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BAL:  bronchoalveolar lavage  
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HIV:  human immunodeficiency virus 
MDR:   multiple drug resistant 
NTM:  non-tuberculous Mycobacteria  
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PSI:  Pneumonia Severity Index  
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Community-acquired pneumonia (CAP) guidelines have improved the management and 
outcomes of patients with CAP, primarily by standardization of initial empiric therapy. But 
current society-published guidelines exclude immunocompromised patients. 
 
Research Question 
There is no concensus regarding the initial management of immunocompromised patients with 
suspected CAP.   
 
Study Design and Methods 
This consensus document was created by a multidisciplinary panel of 45 physicians with 
experience in the management of CAP in immunocompromised patients. The Delphi survey 
methodology was used to reach consensus. 
 
Results 
The panel focused on 21 questions addressing initial management strategies. The panel 
achieved consensus in defining the population, site of care, likely pathogens, microbiological 
work-up, general principles of empiric therapy, and empiric therapy for specific pathogens. 
 
Interpretation 
This document offer general suggestions for the initial management of the immunocompromised 







Guidelines for the management of patients with community-acquired pneumonia (CAP) have 
been published by medical societies from several countries. These guidelines have improved 
the management and outcomes of patients with CAP, primarily by standardization of initial 
empiric therapy. But current society-published CAP guidelines exclude immunocompromised 
patients1-3. Immunocompromised patients have been excluded from guidelines because of their 
need for complex, often individualized, treatment, the expanded spectrum of potential 
pathogens, and their exclusion from the large prospective studies of antibiotic efficacy used to 
support guideline recommendations.  
 
 The number of immunocompromised persons at risk for CAP is increasing due to: (i) 
longer survival of patients with cancer, and recipients of organ transplants; (ii) better recognition 
of immunocompromising conditions; (iii) additional risk groups, such as those receiving novel 
immune-modulating therapies for non-malignant diseases, and (iv) approval of newer 
immunomodulatory agents. It is estimated that 3% of the adult population of the United States is 
immunosuppressed4. Immunocompromising conditions are present in approximately 20 to 30% 
of hospitalized patients with CAP5-7. 
 
 Frequently, the initial management of pneumonia in immuncompromised  patients may 
not occur in specialized tertiary care centers with advanced expertise in their care. Rather, 
immunocompromised patients with symptoms of lower respiratory tract infection often present 
first to general hospitals to be managed by emergency room physicians, internists, or 
hospitalists. These general conditions are identical to those motivating the initial impetus for 
guidelines to treat CAP; namely, the frequency of the condition and the presentation of patients 
in many different health care settings throughout the community.  
 
 Early and adequate empiric treatment of CAP in the general population is associated 
with decreased morbidity and mortality, and the authors attempt here to facilitate application of 
these same principles to patients at high risk of CAP-related complications due to pre-existing 
immune dysfunction. The approaches suggested in this document are based on an extensive 
review of the literature and on the collective experience of the authors. A challenge of reviewing 
the CAP literature in the immunocompromised host is that most publications evaluate outcomes 
of antimicrobial therapy for patients in whom the pathogen causing CAP has been identified. No 
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large, prospective clinical studies comparing different empiric therapies in immunocompromised 
patients exist.   
  
 Susceptibility to specific infections varies widely in immunocompromised patients and 
depends both on the degree of immune suppression and the components of the immune system 
which are affected by the underlying disease and/or medical therapy. In this document we 
attempt to develop a unifying approach to simplify a very complex topic, involving a 
heterogenous population. The objective of this document is to suggest an approach to the initial 




The Delphi survey methodology used to reach consensus. After a full review of the English 
literature in the topic of management of CAP in the ICP, the Delphi questions used in the survey 
were developed (Table 1). The following 5-point Likert scale was used to evaluate agreement or 
disagreement with each proposed answer: Strongly Disagree (1), Disagree (2), Neutral (3), 
Agree (4), Strongly Agree (5). It was considered that a consensus was reached once more than 
75% of participants agreed or strongly agreed with a particular suggestion.  
 
In each round of the Delphi survey, questions regarding the management of CAP in the 
ICP were submitted to all 45 participants of the consensus. To anonymously record participant 
responses and comments, a survey was developed using Research Electronic Data Capture 
(REDCap) that allowed participants to answer with their level of agreement with the suggestion 
and to write specific comments regarding the management suggested by the group. After each 
round, all responses were summarized and an anonymized summary of all the comments was 
produced and sent to each participant. Participants have the opportunity to revise the earlier 
answers considering the anonymized replies of other members of the panel. 
 
After the participants answered the third round of all questions, the range of the answers 
decreased significantly and it was considered that group had reached consensus. At that point, 
a pre-final manuscript was created and submitted to all participants for final comments and 
agreement ratings. After the final comments were incorporated, the manuscript was produced. 
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At each round of the survey, the mean and standard deviation of agreement based on the Likert 
scale for each question was calculated. To evaluate the level of agreement or disagreement for 
each question in a manner that incorporated both mean and standard deviation, a t-statistic for 
each question was calculated. The t-statistic was used to identify which questions had the least 
amount agreement or most controversy. Agreement was visualized by bar charts, and final 





A. Definition of Population 
 
Question 1: Which patients with CAP should be considered immunocompromised? 
We suggest that patients with CAP should be considered to be immunocompromised if they 
have an underlying disease or medical treatment that alters the immune system to the point that 
they are at elevated risk of pneumonia not only by common organisms but also by uncommon 
avirulent or opportunistic organisms. 
 
 No consensus exists regarding which patients should be formally considered 
immunocompromised. Our pragmatic approach is to consider patients to be 
immunocompromised if they are at elevated risk of pneumonia not only by common organisms 
but also by uncommon avirulent or opportunistic organisms. Several practical aspects of 
meeting this definition include the need for comprehensive microbiological testing, the need to 
alter empirical antimicrobial therapy, and the need for adjunctive therapy. Even using this more 
restrictive definition, medical advances supporting longer survival of patients with serious 
conditions and an expanding armamentarium of biological agents results in expanding 
populations of at-risk individuals.  Using this approach, the most common acquired conditions 
that qualify a patient as being immunocompromised are a malignancy that suppresses immune 
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responses (such as lymphoma or leukemia) and advanced HIV infection (CD4 T-lymphocyte 
count <200 cells/µl). The most frequent treatments that qualify a patient as being 
immunocompromised include glucocorticoids, therapies that suppresses B-cell or T-cell 
responses, chemotherapy for malignancy that causes neutropenia, conventional disease-
modifying anti-rheumatic drugs (DMARDs) and biologic agents used to treat a broad range of 
rheumatological, dermatological, gastrointestinal, and autoimmune diseases. Notably, some 
agents (e.g., ibrutinib, alemtuzumab or fludarabine) have persistent immunosuppressive effects, 
long after active treatments is discontinued. A list of patients who should be considered 
immunocompromised is depicted in Table 28-13.  
  
 Most patients who develop CAP have one or more comorbid condition(s) that increase 
their susceptibility to infection. From this perspective, patients with common comorbid conditions 
such as diabetes, chronic lung disease, liver disease, kidney disease or even those who are 
elderly and frail, can be considered relatively immunocompromised. However, patients with this 
degree of immune dysfunction are typically infected with the same spectrum of organisms that 
cause CAP in younger or healthier adults, and their management is covered in the current CAP 
guidelines.  
 
B. Site of Care 
 
Question 2: Which immunocompromised patients with CAP should be admitted to the hospital? 
We suggest that the decision for hospitalization should be based on clinical judgement having a 
low threshold for hospital admission. 
 
 In patients with CAP who are not immunocompromised, the admission decision is 
based on clinical judgment and can be supplemented by using validated severity scores such as 
the Pneumonia Severity Index (PSI) or the CRB-65/CURB-65. Hospitalization of 
immunocompromised patients with CAP is based primarily on clinical judgment, considering that 
CAP severity scores have not been well validated in immunocompromised patients14-16. 
Because immunosuppressive drugs are known to modulate the inflammatory response, the 
typical signs and symptoms of CAP may be attenuated in these patients. The blunted 
inflammatory response may not produce a clear infiltrate at chest x-ray. A CT scan of the chest 
will allow a better definition of the extent of pulmonary infiltrate as well as better recognition of 
complications of pneumonia such abscesses, or pleural effusions. This information, gained with 
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CT scan of the chest, may help in the decision regarding hospitalization. Hypoxia is a 
particularly useful criterion to define site of care. In non-immunocompromised patients with 
CAP, a blood oxygen saturation <92 percent is considered an appropriate threshold for hospital 
admission17. Immunocompromised patients may appear stable at the time of the initial 
evaluation but may deteriorate rapidly, progressing in a few hours from a moderately severe 
pneumonia to a severe pneumonia in need of intensive care. Also, the increased range of 
potential infecting agents renders selection of any empiric regimen much more challenging, 
often requiring parenteral agents. Therefore, our suggestion is for a low threshold for 
hospitalization.  If the patient is considered sufficiently stable for outpatient care, mechanisms 
for close follow up and rapid re-entry to inpatient healthcare should be available.  
 
C. Likely Pathogens 
 
Question 3: What pathogens should be considered “core respiratory pathogens” in patients with 
CAP who are immunocompromised? 
We suggest that the list of core respiratory pathogens able to cause CAP in the 
immunocompromised patient should be the same as those for the non-immunocompromised. 
 
 Immunocompromised patients are susceptible to infection by the same respiratory 
viruses and bacteria that cause CAP in the non-immunocompromised patient. We call these 
"core respiratory pathogens." Common respiratory viral pathogens that cause mild upper 
respiratory tract infections in healthy adults can lead to severe lower respiratory tract infections 
in immunocompromised patients. Table 3 lists the primary groups of “core respiratory 
pathogens” that can cause CAP in immunocompromised patients5,6,18.  
 
Question 4: What pathogens should be considered beyond the “core respiratory pathogens” in 
patients with CAP who are immunocompromised? 
We suggest to focus attention on respiratory pathogens that may cause CAP in the 
immunocompromised patient and for which antimicrobial therapy is available. 
 
 When considering likely etiologies of CAP beyond the core respiratory pathogens, it is 
important to focus attention on organisms that are amenable to antimicrobial treatment. 
Common respiratory pathogens that: 1) may cause CAP in the immunocompromised host and 
2) for which antimicrobial therapy is available, are listed in Table 4. Different types of 
 
 11
immunocompromise conditions will predispose to different types of etiologic agents. A 
description of specific immune deficiencies and the associated respiratory pathogens are 
depicted in Table 5.  
  
 Initial empiric therapy active against these respiratory pathogens may only be 
necessary in selected patients presenting with specific epidemiological, clinical or 
immunological risk factors for infection due to a particular pathogen. These risk factors and the 
specific pathogens that are involved will be discussed below.  
 
D. Microbiological Work-up 
 
Question 5: What microbiological studies should be done in hospitalized patients with CAP who 
are immunocompromised? 
We suggest a comprehensive microbiological work-up with the goal to perform pathogen-
directed therapy and de-escalation of therapy. 
 
 A critical aspect of the management of these patients is initial microbiological work-up 
coupled with empiric therapy, followed by a de-escalation to therapy directed to the causative 
pathogen. De-escalation of therapy is important since continuing a broad-spectrum therapy for 
the full duration of therapy is associated with selection of multi-resistant organisms, increased 
risk of toxicity, drug-drug interactions and impaired antimicrobial stewardship for the entire 
community. As the primary way to perform de-escalation therapy is knowing the pathogen that 
causes pneumonia, a comprehensive microbiological work-up is critically important. Another 
reason to obtain broad microbiological studies is that treatment of opportunistic pathogens is 
complex and often complicated by toxicities and drug-drug interactions.  
 
 The extent of the microbiological work-up should be individualized considering the 
presence of risk factors and likely organisms, as well as local capabilities. During recent years 
the field of diagnostic microbiological techniques has experienced a significant progress. 
Development of rapid diagnostic tests using new molecular techniques and sophisticated new 
laboratory methods such as the matrix-assisted laser desorption ionization–time of flight 
(MALDI-TOF) mass spectrometry are reshaping the clinical microbiology laboratory as well as 
our ability to identify etiologic agents of CAP in immunocompromised patients19. A list of 




Question 6: When should a bronchoscopy with bronchoalveolar lavage be performed in 
hospitalized patients with CAP who are immunocompromised? 
We suggest that the decision to perform a bronchoscopy or bronchoalveolar lavage should be 
individualized. 
 
A bronchoscopy with BAL will be useful even in a clinically unstable patient if the patient 
is at risk for infection with multiple opportunistic pathogens and an experienced team is 
available to perform the procedure. Preferably, a bronchoscopy with BAL should be done early 
so that initial empiric therapy does not alter the culture results. If the bronchoscopy can be 
obtained promptly, a short delay before initiating antibiotic therapy may be acceptable, given 
improved culture yield. In general, the more immunocompromised the host, the greater the 
potential benefit of performing a bronchoscopy with BAL. 
If the etiology of CAP may be defined based on initial x-rays and point of care diagnostic 
testing, the small, but nevertheless clear risk associated with bronchoscopy with BAL may 
outweigh the benefit30. 
 
Question 7: What microbiological studies can be obtained in bronchoalveolar lavage fluid in 
hospitalized patients with CAP who are immunocompromised? 
We suggest that microbiological studies in bronchoalveolar lavage should be ordered according 
to the presence of risk factors for particular pathogens. 
 
 In some institutions a fixed panel of tests is routinely performed in BAL from 
immunocompromised patients with CAP. In other institutions, the tests are ordered considering 
the presence of clinical, radiographic and immunological risk factors for specific organisms. 
Table 731-35 lists microbiological studies that can be done on BAL or tissue from a transbronchial 
lung biopsy together with relevant clinical considerations.  
 
E. Empiric Therapy: General Principles  
 




We suggest that immunocompromised patients without any additional risk factors for drug 
resistant bacteria can receive initial empiric therapy targeting only the core respiratory 
pathogens. 
 
 Although immunocompromised hosts may have unique immunological risk and often 
more frequent nosocomial contact and antibiotic exposure, many immunocompromised patients 
admitted with CAP do not have any additional risk factors for drug resistant bacteria (e.g. 
MRSA, Pseudomonas). For these patients, we suggest initial empiric antimicrobial therapy 
targeting the "core respiratory pathogens" described in Table 3. In these group of patients, the 
initial empiric anti-bacterial therapy would be the same as the initial empiric therapy for 
hospitalized patients with CAP who are not immunocompromised1. Additional empiric treatment 
beyond the core respiratory pathogens should be considered according to the presence of risk 
factors for drug-resistance or opportunistic pathogens and will be discussed in sections below. 
 
Question 9: In which patients with CAP who are immunocompromised should empiric therapy 
be extended beyond the core respiratory pathogens? 
We suggest to extend empiric therapy beyond core respiratory pathogens when 1) risk factors 
for drug resistant organisms or opportunistic pathogens are present and 2) the delay in empiric 
antimicrobial therapy will place the patient at increased risk of mortality. 
 
 In addition to initial empiric treatment for core respiratory pathogens, we suggest 
broader initial coverage when the following factors are met: 1) A resistant bacterium or  an 
opportunistic pathogen is suspected based on the presence of risk factors from findings on 
history or physical examination, laboratory results and/or imaging patterns; AND 2) waiting for 
microbiological identification of the suspected pathogen will significantly delay initiation of 
antimicrobial therapy and may increase the risk of mortality. Other considerations for extending 
initial empiric therapy beyond core pathogens include availability of point of care tests, severity 
of disease at presentation, and use of prophylactic therapy for a particular opportunistic 
pathogen.  
 
 The need for empiric therapy of opportunistic pathogens will continue to evolve as 
more point-of-care tests are developed for rapid diagnosis. Empiric therapy beyond core 
respiratory pathogens may not be necessary if the patient is clinically stable and the local 




Question 10: What role does the severity of pneumonia play in the selection of initial empiric 
therapy? 
We suggest that the presence of severe pneumonia can be used as an indication to start 
empiric therapy for resistant gram positive and gram negative organisms, followed by rapid de-
escalation if no multi-drug resistant pathogen is identified. 
 
 Severity of illness is not by itself an accurate predictor of drug-resistance or 
opportunistic infection in pneumonia. For example, Streptococcus pneumoniae is capable of 
causing life-threatening septic shock, whereas invasive pulmonary aspergillosis may present 
with an indolent, progressive course.    
 
 The impact of severe pneumonia on empiric therapy is the critical need to start early 
with an appropriate antimicrobial therapy, since initial inadequate antibiotic spectrum has been 
identified as an independent risk factor for mortality in CAP. Given this circumstance, the 
presence of severe pneumonia or pneumonia requiring ICU care can be used as a threshold to 
start empiric therapy for resistant Gram-positive organisms (e.g. MRSA) and resistant Gram-
negative organisms (e.g. Pseudomonas). 
 
F. Empiric Therapy: Specific Pathogens 
 
Question 11: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to MRSA? 
We suggest that initial empiric therapy to cover for MRSA should be started in patients with a 
history of colonization or infection with MRSA in the previous twelve months. 
 In patients with a history of colonization or infection with MRSA in the previous 12 
months initial empiric therapy should cover the possibility of infection due to MRSA. There are 
other risk factors reported in the literature for MRSA infection such as prior antibiotic use, recent 
hospitalization, hemodialysis or wound care, but if the local prevalence of MRSA is low, these 
risk factors will each have a low positive predictive value and should not be used to trigger 
empiric anti-MRSA therapy36-40. On the other hand, a single patient who accumulate many of 
these risk factors may have a high likelihood of CAP due to MRSA. Vancomycin or linezolid are 
the first line for initial empiric therapy. In regions with high prevalence of MRSA,  some 
members of the panel will start empiric anti-MRSA therapy in patients requiring ICU admission. 
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A negative MRSA nasal PCR, absence of Gram-positive cocci in clusters on Gram's stain, and a 
negative MRSA respiratory culture can be used to de-escalate anti-MRSA therapy.  
 
Question 12: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of drug-resistant Gram-negative bacilli, including 
Pseudomonas aeruginosa? 
We suggest that initial empiric therapy for immunocompromised patients should cover resistant 
Gram-negative bacilli, including Pseudomonas aeruginosa, if there is a history of colonization or 
infection with a resistant Gram-negative bacilli in the prior twelve months, previous 
hospitalization with exposure to broad-spectrum antibiotics, presence of a tracheostomy, 
neutropenia, or history of pulmonary comorbidity. 
 
 History of colonization or infection with a drug resistant Gram-negative bacilus in the 
previous 12 months, previous hospitalization with exposure to broad spectrum antibiotics, 
presence of a tracheostomy, neutropenia, history of pulmonary comorbidity (e.g. cystic fibrosis, 
bronchiectasis, or recurrent exacerbations of COPD requiring glucocorticoid and antibiotic use) 
have been reported in literature to increase risk of resistant Gram-negative bacili37-42. Patients 
with any of these risk factors should be considered for initial empiric therapy against resistant 
Gram-negative bacilli including P. aeruginosa. Beta-lactam antibiotics with activity against P. 
aeruginosa such as piperacillin-tazobactam or a carbapenem should be used as core therapy. 
However, ceftazidime, which has no reliable activity against S. pneumoniae, should not be used 
as monotherapy43. 
 
Question 13: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to multi-drug resistant (MDR) Gram-negative 
bacilli? 
We suggest that in patients with a recent history of colonization or infection with MDR Gram-
negative bacilli, the initial empiric therapy should cover the possibility of infection due to the 
colonizing MDR Gram-negative bacilli. 
 
 In patients with a recent history of colonization or infection with MDR Gram-negative 
bacilli such as extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceaea, 
carbapenemase-producing Enterobacteriaceae (CRE), MDR Pseudomonas, or MDR 
Acinetobacter, the initial empiric therapy should cover the possibility of infection due to the 
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colonizing MDR Gram-negative bacilli. A knowledge of local susceptibility profile for Gram-
negative bacilli and the most recent susceptibility profile of the colonizing MDR Gram-negative 
bacilli will help in the selection of empiric therapy for these organisms with difficult-to-treat 
resistance. For empiric therapy of MDR Gram-negative bacilli, beta-lactam antibiotics such as 
piperacillin-tazobactam or imipenem, may have to be changed to newer beta-lactam antibiotics 
that have better activity against some of the MDR bacteria. In these patients, consideration 
should be given to the addition of ceftazidime-avibactam, ceftolozane-tazobactam, or 
meropenem-vaborbactam. Adding a polymyxin such as colistin to a traditional beta-lactam is a 
possibility when other agents are not available. In patients treated empirically with these broad 
spectrum agents, we strongly emphasize an extended microbiological workup and prompt de-
escalation of therapy if appropriate. 
 
Question 14: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Pneumocystis jirovecii pneumonia (PCP)? 
We suggest initial empiric therapy should be extended to cover the possibility of PCP in patients 
with diffuse, bilateral, interstitial infiltrates or alveolar opacities and who are not receiving PCP 
prophylaxis and either (1) an HIV host who is newly diagnosed, or not on antiretroviral therapy, 
or with CD4 counts less than 200 cells/µl (or a percentage lower than 14%) or (2) a non-HIV 
host with severely impaired cell-mediated immunity (e.g., glucocorticoids with cytotoxic agents). 
 
 In these patients we suggest the addition of TMP-SMX to the initial regimen. The 
recommended dose for TMP-SMX is 15 to 20 mg/kg/day of the trimethoprim component orally 
or IV given in three or four divided doses44. The dose of TMP-SMX is the same for PCP in the 
HIV patient and PCP in the immunocompromised non-HIV patient. Adjunctive glucocorticoids 
are recommended for HIV patients with a room air PaO2 <70 mmHg and/or an alveolar-arterial 
(A-a) oxygen gradient of ≥35 mmHg44. Corticosteroids are not beneficial in HIV-negative 
patients with PCP45. 
 
Question 15: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Aspergillus? 
We suggest that empiric therapy should cover the possibility of pneumonia due to filamentous 
fungi such as Aspergillus in patients with cancer and chemotherapy with severe and prolonged 
neutropenia and radiographic nodular pattern surrounded by a halo of ground-glass attenuation 




 Voriconazole is considered the first line treatment for patients with documented 
invasive aspergillosis, but we do not suggest empiric voriconazole because these patients are 
also at risk for other filamentous fungi resistant to voriconazole (e.g. mucormycosis)46.  In these 
patients we suggest empiric therapy with liposomal amphotericin at doses of 5 to 7.5 mg/kg 
daily. In patients intolerant to amphotericin, empiric therapy with isavuconazole with an initial 
dose of 200 mg every 8 hours can be used as an alternative47.  
 
 Patients treated with tumor necrosis factor (TNF) inhibitors, such as etanercept, 
infliximab, or adalimumab, are also at risk of fungal pneumonia11,12. In these patients we 
suggest an aggressive diagnostic work-up and treat if a fungus is identified. In the management 
of these patients it is important to discontinue the use of the anti-TNF drug at the time of 
diagnosis of pneumonia to improve the level of immunity of the patient.  
 
Question 16: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mucorales? 
We suggest that empiric therapy should cover the possibility of pneumonia due to filamentous 
fungi such as Mucorales in patients with cancer and chemotherapy with severe and prolonged 
neutropenia and radiographic nodular pattern, or a reverse halo sign, or pleural effusion. 
 
 Empiric therapy for Mucorales is especially important when fungal infection is 
suspected in a patient on voriconazole antifungal prophylaxis.  In these patients we suggest 
liposomal amphotericin as part of the initial empiric regimen at doses of 5 to 7.5 mg/kg daily48. In 
patients intolerant to amphotericin, empiric therapy with isavuconazole with an initial dose of 
200 mg every 8 hours can be used as an alternative47. Voriconazole does not cover 
Mucormycosis and therefore it is not suggested as initial empiric therapy. 
 
Question 17: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Nocardia? 
We suggest that empirical therapy should include the possibility of Nocardia infection in patients 
with heart, lung, liver or hematopoietic stem cell transplant with pneumonia and evidence for a 




 In these patients we suggest the addition of TMP-SMX to the initial empirical therapy 
at a dose of 15 mg/kg IV of the trimethoprim component per day in three or four divided doses49. 
Resistance of Nocardia spp. to TMP-SMX is a rare event50. If TMP-SMX is contraindicated, 
Linezolid also has excellent activity and can be considered for empiric therapy until 
susceptibilities are known50. If initial treatment contains  already a drug with activity against 
Nocardia spp. (e.g. linezolid or imipenem) empiric addition of TMP-SMX is not requested. 
However, TMP-SMX is the drug of choice for definite treatment. 
 
Question 18: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Varicella-zoster virus? 
We suggest that empiric therapy be extended to cover the possibility of CAP due to Varicella-
zoster virus in patients with bilateral reticulonodular infiltrates who also have a vesicular rash. 
 
In these patients we suggest the addition of intravenous acyclovir 10-15 mg/kg IV every 8 hours 
to the initial empiric regimen51.  
 
Question 19: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Cytomegalovirus? 
We suggest that empiric therapy be extended to cover the possibility of CAP due to 
Cytomegalovirus in patients with bilateral interstitial pneumonia after a recent lung transplant or 
hematopoietic stem cell transplant. 
 
In these patients we suggest the addition of ganciclovir to the initial regimen at a dose of 5 
mg/kg IV every 12 hours, with dose adjustment for renal dysfunction52. Elevated plasma CMV 
viral loads are frequent in patients with CMV pneumonitis, but this finding alone is not sufficient 
for diagnosis53. In lung transplant recipients, CMV PCR viral load in BAL is a superior diagnostic 
tool than plasma CMV viral load54. 
 
Question 20: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mycobacterium tuberculosis? 





Pulmonary infections due to mycobacteria such as tuberculosis, are common in patients treated 
with TNF inhibitors and patients with long term high-dose steroids11. But in the case of 
suspected mycobacterial pneumonia we do not suggest treating the patient with empiric 
therapy. We suggest carrying out the indicated microbiological studies and begining treatment 
once the pathogen has been identified. We think that in these patients the risk-benefit of 
expanding empiric therapy with multiple mycobacterial drugs versus waiting to define which 
patients have a mycobacterial infection, is in favor of waiting for microbiological results and 
treating them specifically.  
 
 An exception to this approach would be in patients with HIV infection with a history of 
recent exposure who have other clinical findings and radiographic features compatible with 
tuberculosis infection, and present with severe CAP. In this patients we will start empiric therapy 
for tuberculosis pending microbiologic work-up44.  
 
Question 21: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to parasites? 
We suggest not to start empiric therapy to cover CAP due to parasites. 
 
Parasites that can produce CAP in the immunocompromised host include Strongyloides 
stercoralis and Toxoplasma gondii55,56.  
 
 Pneumonia in patients with Strongyloides hyperinfection syndrome may be due to 
invasion of lung tissue by the filariform larvae or with Gram-negative bacteremia secondary to 
seeding of the blood from the gastrointestinal tract. Patients at risk of Strongyloides 
hyperinfection syndrome include those with solid organ transplantation, hematopoietic stem cell 
transplantation, or patients with high and prolonged doses of corticosteroids (e.g. prednisone 
>20 mg per day, or its equivalent, for longer than 1 month) in combination with cytotoxic agents. 
Patients on this type of immune suppressing therapy, and also those with secondary 
bacteremias, may not have an elevated eosinophil count to raise suspicion of a parasitic 
infection. Therapy with ivermectin is recommended for patients with hyperinfection syndrome55.  
 
 Toxoplasma pneumonia occurs due to reactivation of latent infection in (1) patients 
with HIV infection that is newly diagnosed, and not on antiretroviral therapy or with CD4 counts 
less than 100 cells/µl; or (2) patients with defects in cell-mediated immunity due to high and 
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prolonged doses of corticosteroids in combination with cytotoxic agents. Therapy with 
pyrimethamine and sulfadiazine is recommended for patients with Toxoplasma pneumonia44.  
 
 We think that in these patients the risk benefit of expanding empiric therapy for 
parasitic infections or waiting to define which patients have a parasitic infection favors waiting 




In this document we have developed general suggestions for the initial management of the 
immunocompromised patient who arrives at the hospital with pneumonia. Despite our 
suggestions of empirical therapy for specific pathogens in specific situations, we stress the 
importance of making a concerted effort to establish a rapid and accurate etiologic diagnosis 
and to de-escalate complex therapies once a presumptive pathogen is properly ruled out. It is 
also important to consider local susceptibility patterns when selecting empiric therapy. The 
participants do suggest that, if evidence supports the presence of infections that require highly 
specialized management (e.g. cytomegalovirus or Mucorales), after initial therapy is begun, 
prompt transfer to a tertiary care facility should be strongly considered. Transfer to a specialized 
center may not be necessary if experienced pulmonary and infectious disease specialists are 
available to participate in management. 
  
 An important weakness of this document is the simplification of heterogenous 
conditions that affect different arms of the immune system into a single group of 
immunocompromised patients with CAP. Another limitation is that we were not able to provide 
references that appropriately support several of our suggestions, hence we need to emphasize 
the suggestions offered in this consensus are based primarily on expert opinion. 
 
 In conclusion, we have developed general suggestions for the initial management of 
immunocompromised patients hospitalized with pneumonia. When possible, the care of these 
patients should be carried out by a multidisciplinary group of specialists. Because 
immunocompromised patients have been excluded from prospective randomized studies of 
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Table 1.  Questions addressing initial management strategies for community-acquired 
pneumonia (CAP) in immunocompromised adults. 
A. Definition of Population  
Question 1: Which patients with CAP should be considered immunocompromised? 
B. Site of Care  
Question 2: Which immunocompromised patients with CAP should be admitted to the hospital? 
C. Likely Pathogens  
Question 3: What pathogens should be considered “core respiratory pathogens” in patients 
with CAP who are immunocompromised? 
Question 4: What pathogens should be considered beyond the “core respiratory pathogens” in 
patients with CAP who are immunocompromised? 
D. Microbiological Work -up  
Question 5: What microbiological studies should be done in hospitalized patients with CAP 
who are immunocompromised? 
Question 6: When should a bronchoscopy with bronchoalveolar lavage be performed in 
patients with CAP who are immunocompromised? 
Question 7: What microbiological studies can be obtained in bronchoalveolar lavage in patients 
with CAP who are immunocompromised? 
E. Empiric Therapy: General Principles  
Question 8: What empiric therapy should be started in hospitalized patients with CAP who are 
immunocompromised? 
Question 9: In which patients with CAP who are immunocompromised should empiric therapy 
be extended beyond the core respiratory pathogens? 
Question 10: What role does the severity of pneumonia play in the selection of initial empiric 
therapy? 
F. Empiric Therapy: Specific Pathogens  
Question 11: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to MRSA? 
Question 12: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of drug-resistant Gram-negative bacilli, including 
Pseudomonas aeruginosa? 
Question 13: In which immunocompromised patients should the initial empiric therapy be 
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extended to cover the possibility of CAP due to multi-drug resistant (MDR) Gram-negative 
bacilli? 
Question 14: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Pneumocystis jirovecii pneumonia (PCP)? 
Question 15: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Aspergillus? 
Question 16: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mucorales? 
Question 17: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Nocardia? 
Question 18: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Varicella-zoster virus? 
Question 19: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Cytomegalovirus? 
Question 20: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mycobacterium tuberculosis? 
Question 21: In which immunocompromised patients should the initial empiric therapy be 





Table 2.  Patients with the following conditions should be considered immunocompromised 
Primary immune deficiency diseases 
Active malignancy or malignancy within one year prior to CAP, excluding patients with 
localized skin cancers or early stage cancers (e.g. stage 1 lung cancer) 
Receiving cancer chemotherapy  
HIV infection with a CD4 T-lymphocyte count <200 cells/µl or percentage <14%*8 
Solid organ transplantation  
Hematopoietic stem cell transplantation 
Receiving corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent daily for ≥14 
days or a cumulative dose > 700 mg of prednisone**9,10 
Receiving biologic immune modulators***11,12 
Receiving disease-modifying anti-rheumatic drugs13 or other immunosuppressive drugs (e.g. 
cyclosporin, cyclophosphamide, hydroxychloroquine, methotrexate) 
 
*The association of HIV disease and CAP can be categorized in 3 levels.  
Level 1: Patients with a CD4 T-lymphocyte count >500 cells/µl. These patients are not at 
increased risk of CAP.  
Level 2: Patients with a CD4 T-lymphocyte count between 500 to 200 cells/µl. These 
patients are at increased risk of CAP, but are not considered immunocompromised 
because the etiologic agents are the core CAP pathogens such as Streptococcus 
pneumoniae.   
Level 3: Patients with a CD4 T-lymphocyte count <200 cells/µl. These patients are at risk 
for CAP due to opportunistic pathogens such as PCP. They are considered 
immunocompromised patients with CAP.  
 
**In the case of patients taking steroid and CAP, both the daily dose and the cumulative dose of 
steroids should be considered. The association with CAP can be define in 3 levels. 
Level 1: Doses ≤10 mg of prednisone a day and a cumulative dose of less than 600 mg 
of prednisone or equivalent. These patients are not at increased risk of CAP. 
Level 2: Doses 10 mg to ≤ 20 mg of prednisone a day with a cumulative dose greater 
than 600 mg of prednisone or equivalent at the time of the CAP episode. These patients 
are at increased risk of CAP, but are not considered immunocompromised because the 
etiologic agents are the core CAP pathogens such as Streptococcus pneumoniae.   
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Level 3: Doses ≥20 mg or more of prednisone a day with a cumulative dose greater than 
600 mg of prednisone or equivalent at the time of the CAP episode. These patients are 
at risk for CAP due to opportunistic pathogens such as PCP. They are considered 
immunocompromised patients with CAP. Due to the cumulative dose of at least 600 mg, 
this patients need to be on steroid therapy for at least 3 to 4 weeks to be consider 
fulfilling this condition. 
 
***These drugs are used to treat a wide array of inflammatory conditions and have multiple 
immunological targets. The diverse effects of these drugs include interfering with cell signaling, 
inhibiting cytokine function, interrupting innate immunity, depleting B cells, or inhibiting T-cell 
activation. Specific discussion of these drugs in detail is beyond the scope of this paper. 
However, nearly all immunomodulators carry some risk of infection. Because these 
immunomodulating agents affect different components of the immune system, the risk for 
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   Rhinovirus  
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Table 4:  List of common respiratory pathogens in addition to core respiratory pathogens (as 
described in Table 3) that can cause CAP in the immunocompromised patient and for which 
antimicrobial therapy is available. 
Bacteria  Mycobacteria  Viruses  Fungi  Parasites  
Enterobacteriaceae 
(Including those 

























Mucorales spp.  
Nocardia spp.   Histoplasma spp.  
Rhodococcus equi   Cryptococcus spp.  
   Blastomyces spp.  





Table 5. Specific immune deficiencies and associated respiratory pathogens 
Specific Immune Deficiency  Unique Respiratory Pathogen Associations  
Neutropenia Pseudomonas aeruginosa, Stenotrophomonas maltophilia, other 
Enterobacteriaceae, Streptococcus mitis, Staphylococcus aureus, 
Nocardia spp, Aspergillus and other hyaline molds (Scedosporium, 
Fusarium), yeast-like fungi (Trichosporon), Mucorales, dimorphic 
fungi 
AIDS Pneumocystis jiroveci, Streptococcus pneumoniae, Mycobacterium 
tuberculosis, M. avium-intracellulare complex and other non-
tuberculous mycobacteria, Histoplasma capsulatum, Coccidioides, 
Bartonella, Rhodococcus, Toxoplasma gondii, Cryptococcus 
neoformans, Cryptosporidium, Nocardia, Talaromycosis marneffei, 
Paracoccidioides, Burkholderia, Cytomegalovirus,  Strongyloides 
T-cell depletion (Antithymocyte 
globulin, Alemtuzumab) 
Pneumocystis jiroveci, Streptococcus pneumoniae, Mycobacterium 
tuberculosis, M. avium-intracellulare complex and other non-
tuberculous mycobacteria, Aspergillus and other hyaline molds, 
Mucorales spp, Varicella, Herpes simplex, Cytomegalovirus, 
Histoplasma capsulatum, Coccidioides, Bartonella spp., Toxoplasma 





Myeloma, Therapies that target 
CD19/20, e.g. rituximab) 
Respiratory viruses (Influenza, RSV, HMPV, Parainfluenza, 
Adenovirus, Enterovirus), Encapsulated bacteria (S. pneumoniae, 
Moraxella catarrhalis, Haemophilus influenzae, S. aureus, 
Capnocytophaga, Pasteurella multocida), Cytomegalovirus, 
Pneumocystis 
Calcineurin Inhibitors 
(cyclosporine and tacrolimus) 
Legionella, Nocardia, Aspergillus and other hyaline mold, Mucorales 
spp, Cytomegalovirus, endemic fungi 
Antimetabolites (mycophenolate 
mofetil, azathioprine, 6-MP, 
fludarabine) 
Cytomegalovirus, Varicella, Respiratory viruses (if B-cell 
impairment), Legionella, Nocardia, Aspergillus and other hyaline 
mold, Mucorales spp, endemic fungi, (Pneumocystis– fludarabine) 
Mammalian target of rapamycin 
(mTOR) inhibitors (sirolimus, 
evirolimus) 
Cryptococcus, Pneumocystis 
Tumor Necrosis Factor (TNF) Endemic fungi, Aspergillus, Mycobacteria (tuberculous and non-
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Inhibitors tuberculous), Varicella, Nocardia, Pneumocystis 
Janus kinase (JAK) Signaling 
Inhibitors (e.g. Ibrutinib, Dasatinib) 
Pneumocystis, mold, Cytomegalovirus 
Corticosteroids Bacteria, esp. Pseudomonas aeruginosa, Pneumocystis jiroveci, 
Staphylococcus aureus, Mycobacteria, Aspergillus and other hyaline 
molds, Mucorales spp, Cytomegalovirus , Varicella, Herpes simplex, 
Cytomegalovirus, Histoplasma capsulatum, Coccidioides, 
Cryptococcus neoformans, Nocardia, Legionella, Strongyloides 
Other Natalizumab (Cryptococcus), vedolizumab (M. tuberculosis), 
Tocilizumab (unknown), Ustekinumab (theoretical CMV), 
Secukinumab (theoretical mold), eculizumab (Pseudomonas, mold), 





Table 6. Microbiological studies that can be obtained in immunocompromised patients 
hospitalized with CAP 
Sputum samples for bacterial, mycobacterial, and fungal stains and cul tures  
Comments: Sputum can be induced using inhaled isotonic or preferably hypertonic saline for 
certain pathogens (e.g., MTB, PCP) in order to avoid invasive procedures. Sputum samples 
can be tested using PCR for detection of MTB or PCP20,21.  
Nasopharyngeal swab with PCR multiplex for respirat ory viruses  
Comments: A negative nasopharyngeal PCR does not rule out viral pneumonia.  If the 
suspicion is high, perform the PCR on bronchoscopic samples22,23. The finding of a virus by 
PCR does not rule out bacterial infection. 
Nasopharyngeal swab with PCR multiplex for atypical  bacteria  
Comments: Atypical pathogens such as Legionella, Chlamydophila, or Mycoplasma, can also 
be identified in oropharyngeal samples. 
Nasal PCR for MRSA  
Comments: Use in conjunction with a respiratory sample. A negative MRSA nasal PCR, the 
absence of Gram-positive cocci in clusters on Gram's stain, and a negative MRSA respiratory 
culture make MRSA pneumonia extremely unlikely. 
Blood cultures times two (at least) 30 minutes apar t  
Comments: If there is a PORT or central line or PICC line, to define the presence of line 
infection, perform blood cultures from a peripheral vein and from the catheter lumens at the 
same time to calculate “time to positivity"24. The separation of samples over time improve 
bacterial detection in case of intermittent bacteremia25. 
Urinary antigen for Streptococcus pneumoniae 
Comments: The recent administration of pneumococcal vaccine (within days) will produce a 
positive urinary antigen for Streptococcus pneumoniae.  
Urinary antigen for Legionella  
Comments: Detects only Legionella pneumophila serotype 1. Other Gram-negative bacteria 
may generate a false positive test26. Obtain respiratory samples for culture and PCR to detect 
other species of Legionella or serotypes if clinically indicated.  
Urinary antigen for Histoplasma capsulatum  
Comments: Very useful for disseminated disease. Cross reaction with blastomycosis. 
Serum antigen for Cryptococcus neoformans 
Comments: A serum cryptococcal antigen test may be negative in a patient with documented 
cryptococcal pneumonia.  
Serum galactomannan antigen  
Comments: Aspergillus cell wall contains the polysaccharide galactomannan.  Also elevated 
in Fusarium, Penicillium, blastomycosis, and histoplasmosis. False positives may occur with 
IVIG, transfusions and some beta-lactam antibiotics27. 
Serum 1,3 -Beta-D-glucan  
Comments: Beta-D-glucan is a cell component of several fungi. It screens for Aspergillus 
spp., Candida spp., PCP, and other fungi. It does not detect mucormycosis. False positives 
may occur with IVIG, hemodialysis with cellulose, albumin, infections by Pseudomonas, and 
some beta-lactam antibiotics27. 
Swabs of vesicular or ulcerated skin lesions for vi ral PCR and cultures  
Comments: A positive PCR for HSV or VZV from skin lesions is highly correlated with herpes 
or varicella pneumonia. 
Biopsy of skin lesion for microbiology & pathology  
Comments: Sample must be sent to microbiology and pathology for stains and cultures for 
viruses, bacteria, mycobacteria, fungi and parasites. 
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Viral load for CMV (PCR)  
Comments: Obtain only if clinical suspicion is high. CMV reactivation is common in acute 
illness and the presence of copies of CMV in plasma does not necessarily indicate invasive 
disease. On the other hand, the absence of viremia makes CMV pneumonitis less likely28. 
Viral load for Adenovi rus  
Comments: Obtain only if clinical suspicion is high29. 
Serology for Histoplasmosis, Coccidioidomycosis and  Blastomycosis  
Comments: Fungal serology is not generally recommended in immunosuppressed patients 





Table 7. Microbiological studies in BAL fluid or tranbronchial lung biopsy 
Bacteria Gram’s stain and culture    
Comments: A negative stain and culture of MDR pathogens (e.g. MRSA) can be used for de-
escalation of therapy unless antibiotics have been given for >48 hours. 
MRSA PCR 
Comments: A negative PCR for MRSA can be used for de-escalation of anti-MRSA therapy 
unless antibiotics have been given for >48 hours31. 
AFB stains and culture for tuberculous and non -tuberculous mycobacteria  
Comments: If positive AFB stain, nucleic acid amplification (NAA) tests allows for rapid 
diagnosis. NAA test can be performed if the AFB stain is negative and the suspicion of 
disease is high20. 
Nocardia stains and culture  
Comments: AFB stain may be weakly positive. 
Fungal stains and culture  
Comments: Since Aspergillus can colonize the airways, positive stains or culture of 
Aspergillus species from respiratory samples do not necessarily indicate disease27. 
PCP stains and PCR  
Comments: In patients with PCP, the sensitivity of staining is higher in HIV-infected patients 
when compared to HIV-uninfected patients. A positive PCR may occur in patients colonized 
with PCP. In non-HIV patients, a negative PCR can be use to discontinue anti-PCP therapy32. 
Respiratory Viral Panel with multiplex PCR  
Comments: Viruses can be detected in BAL by PCR in a patient with a negative 
nasopharyngeal swab PCR for the same virus22,23. 
Atypical pathogens panel with multiplex PCR  
Comments: A positive PCR is considered diagnostic for atypical pneumonia since pathogens 
such as Legionella, Chlamydophila, or Mycoplasma rarely colonize the airway.  
Galactomannan Antigen  
Comments: The cell wall of Aspergillus contain the polysaccharide galactomannan. Other 
fungi that contain galactomannan include Histoplasma capsulatum, Penicillium species and 
Fusarium species. False positive levels may occur in BAL samples with some beta-lactam 
antibiotics27.  
Aspergillus PC R  
Comments: The high sensitivity of PCR produce a high negative predictive value, making the 
diagnosis unlikely with a negative test27.  
(1,3)-Beta-D-glucan  
Comments: It is considered a poor screening tool for the diagnosis of invasive fungal 
infections due to its low positive predictive value27. 
CMV PCR 
Comments: Quantitative PCR analysis in BAL fluid may help to differentiate between CMV 
pneumonia (high viral load) versus CMV pulmonary shedding without pneumonia (low viral 
load) but cut-off levels are not defined33. 
Cellular analysis  
Comments: A predominantly inflammatory cellular pattern in the BAL with neutrophil 
pleocytosis can be used as a predictor of bacterial etiology34,35. 
Histopathology  
Comments: Routine hematoxylin and eosin (H&E) staining, special stains, and culture for 
viruses, bacteria, mycobacteria, fungi and parasites. 
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BAL: bronchoalveolar lavage 
CAP: community-acquired pneumonia 
CMV: Cytomegalovirus
CRE: carbapenemase-producing Enterobacteriaceae 
DMARDs: disease-modifying anti-rheumatic drugs
ESBL: extended spectrum beta-lactamase 
HIV: human immunodeficiency virus
MDR: multiple drug resistant
NTM: non-tuberculous Mycobacteria 
PCP: Pneumocystis jirovecii 
PCR: polymerase chain reaction
PSI: Pneumonia Severity Index 
TMP-SMX: trimethoprim-sulfamethoxazole
TNF: tumor necrosis factor 
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BAL: bronchoalveolar lavage 
CAP: community-acquired pneumonia 
CMV: Cytomegalovirus
CRE: carbapenemase-producing Enterobacteriaceae 
DMARDs: disease-modifying anti-rheumatic drugs
ESBL: extended spectrum beta-lactamase 
HIV: human immunodeficiency virus
MDR: multiple drug resistant
NTM: non-tuberculous Mycobacteria 
PCP: Pneumocystis jirovecii 
PCR: polymerase chain reaction
PSI: Pneumonia Severity Index 
TMP-SMX: trimethoprim-sulfamethoxazole
TNF: tumor necrosis factor 
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Community-acquired pneumonia (CAP) guidelines have improved the management and 
outcomes of patients with CAP, primarily by standardization of initial empiric therapy. But 
current society-published guidelines exclude immunocompromised patients.
Research Question
There is no concensus regarding the initial management of immunocompromised patients with 
suspected CAP.  
Study Design and Methods
This consensus document was created by a multidisciplinary panel of 45 physicians with 
experience in the management of CAP in immunocompromised patients. The Delphi survey 
methodology was used to reach consensus.
Results
The panel focused on 21 questions addressing initial management strategies. The panel 
achieved consensus in defining the population, site of care, likely pathogens, microbiological 
work-up, general principles of empiric therapy, and empiric therapy for specific pathogens.
Interpretation
This document offer general suggestions for the initial management of the immunocompromised 
patient who arrives at the hospital with pneumonia.
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Guidelines for the management of patients with community-acquired pneumonia (CAP) have 
been published by medical societies from several countries. These guidelines have improved 
the management and outcomes of patients with CAP, primarily by standardization of initial 
empiric therapy. But current society-published CAP guidelines exclude immunocompromised 
patients1-3. Immunocompromised patients have been excluded from guidelines because of their 
need for complex, often individualized, treatment, the expanded spectrum of potential 
pathogens, and their exclusion from the large prospective studies of antibiotic efficacy used to 
support guideline recommendations. 
The number of immunocompromised persons at risk for CAP is increasing due to: (i) 
longer survival of patients with cancer, and recipients of organ transplants; (ii) better recognition 
of immunocompromising conditions; (iii) additional risk groups, such as those receiving novel 
immune-modulating therapies for non-malignant diseases, and (iv) approval of newer 
immunomodulatory agents. It is estimated that 3% of the adult population of the United States is 
immunosuppressed4. Immunocompromising conditions are present in approximately 20 to 30% 
of hospitalized patients with CAP5-7.
Frequently, the initial management of pneumonia in immuncompromised  patients may 
not occur in specialized tertiary care centers with advanced expertise in their care. Rather, 
immunocompromised patients with symptoms of lower respiratory tract infection often present 
first to general hospitals to be managed by emergency room physicians, internists, or 
hospitalists. These general conditions are identical to those motivating the initial impetus for 
guidelines to treat CAP; namely, the frequency of the condition and the presentation of patients 
in many different health care settings throughout the community. 
Early and adequate empiric treatment of CAP in the general population is associated 
with decreased morbidity and mortality, and the authors attempt here to facilitate application of 
these same principles to patients at high risk of CAP-related complications due to pre-existing 
immune dysfunction. The approaches suggested in this document are based on an extensive 
review of the literature and on the collective experience of the authors. A challenge of reviewing 
the CAP literature in the immunocompromised host is that most publications evaluate outcomes 
of antimicrobial therapy for patients in whom the pathogen causing CAP has been identified. No 
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large, prospective clinical studies comparing different empiric therapies in immunocompromised 
patients exist. 
Susceptibility to specific infections varies widely in immunocompromised patients and 
depends both on the degree of immune suppression and the components of the immune system 
which are affected by the underlying disease and/or medical therapy. In this document we 
attempt to develop a unifying approach to simplify a very complex topic, involving a 
heterogenous population. The objective of this document is to suggest an approach to the initial 
management of immunocompromised patients with suspected CAP.  
METHODS
The Delphi survey methodology used to reach consensus. After a full review of the English 
literature in the topic of management of CAP in the ICP, the Delphi questions used in the survey 
were developed (Table 1). The following 5-point Likert scale was used to evaluate agreement or 
disagreement with each proposed answer: Strongly Disagree (1), Disagree (2), Neutral (3), 
Agree (4), Strongly Agree (5). It was considered that a consensus was reached once more than 
75% of participants agreed or strongly agreed with a particular suggestion. 
In each round of the Delphi survey, questions regarding the management of CAP in the 
ICP were submitted to all 45 participants of the consensus. To anonymously record participant 
responses and comments, a survey was developed using Research Electronic Data Capture 
(REDCap) that allowed participants to answer with their level of agreement with the suggestion 
and to write specific comments regarding the management suggested by the group. After each 
round, all responses were summarized and an anonymized summary of all the comments was 
produced and sent to each participant. Participants have the opportunity to revise the earlier 
answers considering the anonymized replies of other members of the panel.
After the participants answered the third round of all questions, the range of the answers 
decreased significantly and it was considered that group had reached consensus. At that point, 
a pre-final manuscript was created and submitted to all participants for final comments and 
agreement ratings. After the final comments were incorporated, the manuscript was produced. 
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Further details regarding the Delphi survey methodology and rounds are in the supplementary 
material.
Statistical analysis
At each round of the survey, the mean and standard deviation of agreement based on the Likert 
scale for each question was calculated. To evaluate the level of agreement or disagreement for 
each question in a manner that incorporated both mean and standard deviation, a t-statistic for 
each question was calculated. The t-statistic was used to identify which questions had the least 
amount agreement or most controversy. Agreement was visualized by bar charts, and final 
agreement was reported as percentage of participants who responded as Agree or Strongly 
Agree.
RESULTS
A. Definition of Population
Question 1: Which patients with CAP should be considered immunocompromised?
We suggest that patients with CAP should be considered to be immunocompromised if they 
have an underlying disease or medical treatment that alters the immune system to the point that 
they are at elevated risk of pneumonia not only by common organisms but also by uncommon 
avirulent or opportunistic organisms.
No consensus exists regarding which patients should be formally considered 
immunocompromised. Our pragmatic approach is to consider patients to be 
immunocompromised if they are at elevated risk of pneumonia not only by common organisms 
but also by uncommon avirulent or opportunistic organisms. Several practical aspects of 
meeting this definition include the need for comprehensive microbiological testing, the need to 
alter empirical antimicrobial therapy, and the need for adjunctive therapy. Even using this more 
restrictive definition, medical advances supporting longer survival of patients with serious 
conditions and an expanding armamentarium of biological agents results in expanding 
populations of at-risk individuals.  Using this approach, the most common acquired conditions 
that qualify a patient as being immunocompromised are a malignancy that suppresses immune 
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responses (such as lymphoma or leukemia) and advanced HIV infection (CD4 T-lymphocyte 
count <200 cells/µl). The most frequent treatments that qualify a patient as being 
immunocompromised include glucocorticoids, therapies that suppresses B-cell or T-cell 
responses, chemotherapy for malignancy that causes neutropenia, conventional disease-
modifying anti-rheumatic drugs (DMARDs) and biologic agents used to treat a broad range of 
rheumatological, dermatological, gastrointestinal, and autoimmune diseases. Notably, some 
agents (e.g., ibrutinib, alemtuzumab or fludarabine) have persistent immunosuppressive effects, 
long after active treatments is discontinued. A list of patients who should be considered 
immunocompromised is depicted in Table 28-13. 
Most patients who develop CAP have one or more comorbid condition(s) that increase 
their susceptibility to infection. From this perspective, patients with common comorbid conditions 
such as diabetes, chronic lung disease, liver disease, kidney disease or even those who are 
elderly and frail, can be considered relatively immunocompromised. However, patients with this 
degree of immune dysfunction are typically infected with the same spectrum of organisms that 
cause CAP in younger or healthier adults, and their management is covered in the current CAP 
guidelines. 
B. Site of Care
Question 2: Which immunocompromised patients with CAP should be admitted to the hospital?
We suggest that the decision for hospitalization should be based on clinical judgement having a 
low threshold for hospital admission.
In patients with CAP who are not immunocompromised, the admission decision is 
based on clinical judgment and can be supplemented by using validated severity scores such as 
the Pneumonia Severity Index (PSI) or the CRB-65/CURB-65. Hospitalization of 
immunocompromised patients with CAP is based primarily on clinical judgment, considering that 
CAP severity scores have not been well validated in immunocompromised patients14-16. 
Because immunosuppressive drugs are known to modulate the inflammatory response, the 
typical signs and symptoms of CAP may be attenuated in these patients. The blunted 
inflammatory response may not produce a clear infiltrate at chest x-ray. A CT scan of the chest 
will allow a better definition of the extent of pulmonary infiltrate as well as better recognition of 
complications of pneumonia such abscesses, or pleural effusions. This information, gained with 
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CT scan of the chest, may help in the decision regarding hospitalization. Hypoxia is a 
particularly useful criterion to define site of care. In non-immunocompromised patients with 
CAP, a blood oxygen saturation <92 percent is considered an appropriate threshold for hospital 
admission17. Immunocompromised patients may appear stable at the time of the initial 
evaluation but may deteriorate rapidly, progressing in a few hours from a moderately severe 
pneumonia to a severe pneumonia in need of intensive care. Also, the increased range of 
potential infecting agents renders selection of any empiric regimen much more challenging, 
often requiring parenteral agents. Therefore, our suggestion is for a low threshold for 
hospitalization.  If the patient is considered sufficiently stable for outpatient care, mechanisms 
for close follow up and rapid re-entry to inpatient healthcare should be available. 
C. Likely Pathogens
Question 3: What pathogens should be considered “core respiratory pathogens” in patients with 
CAP who are immunocompromised?
We suggest that the list of core respiratory pathogens able to cause CAP in the 
immunocompromised patient should be the same as those for the non-immunocompromised.
Immunocompromised patients are susceptible to infection by the same respiratory 
viruses and bacteria that cause CAP in the non-immunocompromised patient. We call these 
"core respiratory pathogens." Common respiratory viral pathogens that cause mild upper 
respiratory tract infections in healthy adults can lead to severe lower respiratory tract infections 
in immunocompromised patients. Table 3 lists the primary groups of “core respiratory 
pathogens” that can cause CAP in immunocompromised patients5,6,18. 
Question 4: What pathogens should be considered beyond the “core respiratory pathogens” in 
patients with CAP who are immunocompromised?
We suggest to focus attention on respiratory pathogens that may cause CAP in the 
immunocompromised patient and for which antimicrobial therapy is available.
When considering likely etiologies of CAP beyond the core respiratory pathogens, it is 
important to focus attention on organisms that are amenable to antimicrobial treatment. 
Common respiratory pathogens that: 1) may cause CAP in the immunocompromised host and 
2) for which antimicrobial therapy is available, are listed in Table 4. Different types of 
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immunocompromise conditions will predispose to different types of etiologic agents. A 
description of specific immune deficiencies and the associated respiratory pathogens are 
depicted in Table 5. 
Initial empiric therapy active against these respiratory pathogens may only be 
necessary in selected patients presenting with specific epidemiological, clinical or 
immunological risk factors for infection due to a particular pathogen. These risk factors and the 
specific pathogens that are involved will be discussed below. 
D. Microbiological Work-up
Question 5: What microbiological studies should be done in hospitalized patients with CAP who 
are immunocompromised?
We suggest a comprehensive microbiological work-up with the goal to perform pathogen-
directed therapy and de-escalation of therapy.
A critical aspect of the management of these patients is initial microbiological work-up 
coupled with empiric therapy, followed by a de-escalation to therapy directed to the causative 
pathogen. De-escalation of therapy is important since continuing a broad-spectrum therapy for 
the full duration of therapy is associated with selection of multi-resistant organisms, increased 
risk of toxicity, drug-drug interactions and impaired antimicrobial stewardship for the entire 
community. As the primary way to perform de-escalation therapy is knowing the pathogen that 
causes pneumonia, a comprehensive microbiological work-up is critically important. Another 
reason to obtain broad microbiological studies is that treatment of opportunistic pathogens is 
complex and often complicated by toxicities and drug-drug interactions. 
The extent of the microbiological work-up should be individualized considering the 
presence of risk factors and likely organisms, as well as local capabilities. During recent years 
the field of diagnostic microbiological techniques has experienced a significant progress. 
Development of rapid diagnostic tests using new molecular techniques and sophisticated new 
laboratory methods such as the matrix-assisted laser desorption ionization–time of flight 
(MALDI-TOF) mass spectrometry are reshaping the clinical microbiology laboratory as well as 
our ability to identify etiologic agents of CAP in immunocompromised patients19. A list of 
common microbiological studies with relevant clinical considerations is depicted in Table 620-29.
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Question 6: When should a bronchoscopy with bronchoalveolar lavage be performed in 
hospitalized patients with CAP who are immunocompromised?
We suggest that the decision to perform a bronchoscopy or bronchoalveolar lavage should be 
individualized.
A bronchoscopy with BAL will be useful even in a clinically unstable patient if the patient 
is at risk for infection with multiple opportunistic pathogens and an experienced team is 
available to perform the procedure. Preferably, a bronchoscopy with BAL should be done early 
so that initial empiric therapy does not alter the culture results. If the bronchoscopy can be 
obtained promptly, a short delay before initiating antibiotic therapy may be acceptable, given 
improved culture yield. In general, the more immunocompromised the host, the greater the 
potential benefit of performing a bronchoscopy with BAL.
If the etiology of CAP may be defined based on initial x-rays and point of care diagnostic 
testing, the small, but nevertheless clear risk associated with bronchoscopy with BAL may 
outweigh the benefit30.
Question 7: What microbiological studies can be obtained in bronchoalveolar lavage fluid in 
hospitalized patients with CAP who are immunocompromised?
We suggest that microbiological studies in bronchoalveolar lavage should be ordered according 
to the presence of risk factors for particular pathogens.
In some institutions a fixed panel of tests is routinely performed in BAL from 
immunocompromised patients with CAP. In other institutions, the tests are ordered considering 
the presence of clinical, radiographic and immunological risk factors for specific organisms. 
Table 731-35 lists microbiological studies that can be done on BAL or tissue from a transbronchial 
lung biopsy together with relevant clinical considerations. 
E. Empiric Therapy: General Principles
Question 8: What empiric therapy should be started in hospitalized patients with CAP who are 
immunocompromised?
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We suggest that immunocompromised patients without any additional risk factors for drug 
resistant bacteria can receive initial empiric therapy targeting only the core respiratory 
pathogens.
Although immunocompromised hosts may have unique immunological risk and often 
more frequent nosocomial contact and antibiotic exposure, many immunocompromised patients 
admitted with CAP do not have any additional risk factors for drug resistant bacteria (e.g. 
MRSA, Pseudomonas). For these patients, we suggest initial empiric antimicrobial therapy 
targeting the "core respiratory pathogens" described in Table 3. In these group of patients, the 
initial empiric anti-bacterial therapy would be the same as the initial empiric therapy for 
hospitalized patients with CAP who are not immunocompromised1. Additional empiric treatment 
beyond the core respiratory pathogens should be considered according to the presence of risk 
factors for drug-resistance or opportunistic pathogens and will be discussed in sections below.
Question 9: In which patients with CAP who are immunocompromised should empiric therapy 
be extended beyond the core respiratory pathogens?
We suggest to extend empiric therapy beyond core respiratory pathogens when 1) risk factors 
for drug resistant organisms or opportunistic pathogens are present and 2) the delay in empiric 
antimicrobial therapy will place the patient at increased risk of mortality.
In addition to initial empiric treatment for core respiratory pathogens, we suggest 
broader initial coverage when the following factors are met: 1) A resistant bacterium or  an 
opportunistic pathogen is suspected based on the presence of risk factors from findings on 
history or physical examination, laboratory results and/or imaging patterns; AND 2) waiting for 
microbiological identification of the suspected pathogen will significantly delay initiation of 
antimicrobial therapy and may increase the risk of mortality. Other considerations for extending 
initial empiric therapy beyond core pathogens include availability of point of care tests, severity 
of disease at presentation, and use of prophylactic therapy for a particular opportunistic 
pathogen. 
The need for empiric therapy of opportunistic pathogens will continue to evolve as 
more point-of-care tests are developed for rapid diagnosis. Empiric therapy beyond core 
respiratory pathogens may not be necessary if the patient is clinically stable and the local 
setting allows for rapid microbiological diagnostic tests. 
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Question 10: What role does the severity of pneumonia play in the selection of initial empiric 
therapy?
We suggest that the presence of severe pneumonia can be used as an indication to start 
empiric therapy for resistant gram positive and gram negative organisms, followed by rapid de-
escalation if no multi-drug resistant pathogen is identified.
Severity of illness is not by itself an accurate predictor of drug-resistance or 
opportunistic infection in pneumonia. For example, Streptococcus pneumoniae is capable of 
causing life-threatening septic shock, whereas invasive pulmonary aspergillosis may present 
with an indolent, progressive course.   
The impact of severe pneumonia on empiric therapy is the critical need to start early 
with an appropriate antimicrobial therapy, since initial inadequate antibiotic spectrum has been 
identified as an independent risk factor for mortality in CAP. Given this circumstance, the 
presence of severe pneumonia or pneumonia requiring ICU care can be used as a threshold to 
start empiric therapy for resistant Gram-positive organisms (e.g. MRSA) and resistant Gram-
negative organisms (e.g. Pseudomonas).
F. Empiric Therapy: Specific Pathogens
Question 11: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to MRSA?
We suggest that initial empiric therapy to cover for MRSA should be started in patients with a 
history of colonization or infection with MRSA in the previous twelve months.
In patients with a history of colonization or infection with MRSA in the previous 12 
months initial empiric therapy should cover the possibility of infection due to MRSA. There are 
other risk factors reported in the literature for MRSA infection such as prior antibiotic use, recent 
hospitalization, hemodialysis or wound care, but if the local prevalence of MRSA is low, these 
risk factors will each have a low positive predictive value and should not be used to trigger 
empiric anti-MRSA therapy36-40. On the other hand, a single patient who accumulate many of 
these risk factors may have a high likelihood of CAP due to MRSA. Vancomycin or linezolid are 
the first line for initial empiric therapy. In regions with high prevalence of MRSA,  some 
members of the panel will start empiric anti-MRSA therapy in patients requiring ICU admission. 
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A negative MRSA nasal PCR, absence of Gram-positive cocci in clusters on Gram's stain, and a 
negative MRSA respiratory culture can be used to de-escalate anti-MRSA therapy. 
Question 12: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of drug-resistant Gram-negative bacilli, including 
Pseudomonas aeruginosa?
We suggest that initial empiric therapy for immunocompromised patients should cover resistant 
Gram-negative bacilli, including Pseudomonas aeruginosa, if there is a history of colonization or 
infection with a resistant Gram-negative bacilli in the prior twelve months, previous 
hospitalization with exposure to broad-spectrum antibiotics, presence of a tracheostomy, 
neutropenia, or history of pulmonary comorbidity.
History of colonization or infection with a drug resistant Gram-negative bacilus in the 
previous 12 months, previous hospitalization with exposure to broad spectrum antibiotics, 
presence of a tracheostomy, neutropenia, history of pulmonary comorbidity (e.g. cystic fibrosis, 
bronchiectasis, or recurrent exacerbations of COPD requiring glucocorticoid and antibiotic use) 
have been reported in literature to increase risk of resistant Gram-negative bacili37-42. Patients 
with any of these risk factors should be considered for initial empiric therapy against resistant 
Gram-negative bacilli including P. aeruginosa. Beta-lactam antibiotics with activity against P. 
aeruginosa such as piperacillin-tazobactam or a carbapenem should be used as core therapy. 
However, ceftazidime, which has no reliable activity against S. pneumoniae, should not be used 
as monotherapy43.
Question 13: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to multi-drug resistant (MDR) Gram-negative 
bacilli?
We suggest that in patients with a recent history of colonization or infection with MDR Gram-
negative bacilli, the initial empiric therapy should cover the possibility of infection due to the 
colonizing MDR Gram-negative bacilli.
In patients with a recent history of colonization or infection with MDR Gram-negative 
bacilli such as extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceaea, 
carbapenemase-producing Enterobacteriaceae (CRE), MDR Pseudomonas, or MDR 
Acinetobacter, the initial empiric therapy should cover the possibility of infection due to the 
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colonizing MDR Gram-negative bacilli. A knowledge of local susceptibility profile for Gram-
negative bacilli and the most recent susceptibility profile of the colonizing MDR Gram-negative 
bacilli will help in the selection of empiric therapy for these organisms with difficult-to-treat 
resistance. For empiric therapy of MDR Gram-negative bacilli, beta-lactam antibiotics such as 
piperacillin-tazobactam or imipenem, may have to be changed to newer beta-lactam antibiotics 
that have better activity against some of the MDR bacteria. In these patients, consideration 
should be given to the addition of ceftazidime-avibactam, ceftolozane-tazobactam, or 
meropenem-vaborbactam. Adding a polymyxin such as colistin to a traditional beta-lactam is a 
possibility when other agents are not available. In patients treated empirically with these broad 
spectrum agents, we strongly emphasize an extended microbiological workup and prompt de-
escalation of therapy if appropriate.
Question 14: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Pneumocystis jirovecii pneumonia (PCP)?
We suggest initial empiric therapy should be extended to cover the possibility of PCP in patients 
with diffuse, bilateral, interstitial infiltrates or alveolar opacities and who are not receiving PCP 
prophylaxis and either (1) an HIV host who is newly diagnosed, or not on antiretroviral therapy, 
or with CD4 counts less than 200 cells/µl (or a percentage lower than 14%) or (2) a non-HIV 
host with severely impaired cell-mediated immunity (e.g., glucocorticoids with cytotoxic agents).
In these patients we suggest the addition of TMP-SMX to the initial regimen. The 
recommended dose for TMP-SMX is 15 to 20 mg/kg/day of the trimethoprim component orally 
or IV given in three or four divided doses44. The dose of TMP-SMX is the same for PCP in the 
HIV patient and PCP in the immunocompromised non-HIV patient. Adjunctive glucocorticoids 
are recommended for HIV patients with a room air PaO2 <70 mmHg and/or an alveolar-arterial 
(A-a) oxygen gradient of ≥35 mmHg44. Corticosteroids are not beneficial in HIV-negative 
patients with PCP45.
Question 15: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Aspergillus?
We suggest that empiric therapy should cover the possibility of pneumonia due to filamentous 
fungi such as Aspergillus in patients with cancer and chemotherapy with severe and prolonged 
neutropenia and radiographic nodular pattern surrounded by a halo of ground-glass attenuation 
and/or cavitation. 
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Voriconazole is considered the first line treatment for patients with documented 
invasive aspergillosis, but we do not suggest empiric voriconazole because these patients are 
also at risk for other filamentous fungi resistant to voriconazole (e.g. mucormycosis)46.  In these 
patients we suggest empiric therapy with liposomal amphotericin at doses of 5 to 7.5 mg/kg 
daily. In patients intolerant to amphotericin, empiric therapy with isavuconazole with an initial 
dose of 200 mg every 8 hours can be used as an alternative47. 
Patients treated with tumor necrosis factor (TNF) inhibitors, such as etanercept, 
infliximab, or adalimumab, are also at risk of fungal pneumonia11,12. In these patients we 
suggest an aggressive diagnostic work-up and treat if a fungus is identified. In the management 
of these patients it is important to discontinue the use of the anti-TNF drug at the time of 
diagnosis of pneumonia to improve the level of immunity of the patient. 
Question 16: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mucorales?
We suggest that empiric therapy should cover the possibility of pneumonia due to filamentous 
fungi such as Mucorales in patients with cancer and chemotherapy with severe and prolonged 
neutropenia and radiographic nodular pattern, or a reverse halo sign, or pleural effusion.
Empiric therapy for Mucorales is especially important when fungal infection is 
suspected in a patient on voriconazole antifungal prophylaxis.  In these patients we suggest 
liposomal amphotericin as part of the initial empiric regimen at doses of 5 to 7.5 mg/kg daily48. In 
patients intolerant to amphotericin, empiric therapy with isavuconazole with an initial dose of 
200 mg every 8 hours can be used as an alternative47. Voriconazole does not cover 
Mucormycosis and therefore it is not suggested as initial empiric therapy.
Question 17: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Nocardia?
We suggest that empirical therapy should include the possibility of Nocardia infection in patients 
with heart, lung, liver or hematopoietic stem cell transplant with pneumonia and evidence for a 
lung or brain abscess, and who have not been receiving prophylaxis with TMP-SMX.
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In these patients we suggest the addition of TMP-SMX to the initial empirical therapy 
at a dose of 15 mg/kg IV of the trimethoprim component per day in three or four divided doses49. 
Resistance of Nocardia spp. to TMP-SMX is a rare event50. If TMP-SMX is contraindicated, 
Linezolid also has excellent activity and can be considered for empiric therapy until 
susceptibilities are known50. If initial treatment contains  already a drug with activity against 
Nocardia spp. (e.g. linezolid or imipenem) empiric addition of TMP-SMX is not requested. 
However, TMP-SMX is the drug of choice for definite treatment.
Question 18: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Varicella-zoster virus?
We suggest that empiric therapy be extended to cover the possibility of CAP due to Varicella-
zoster virus in patients with bilateral reticulonodular infiltrates who also have a vesicular rash.
In these patients we suggest the addition of intravenous acyclovir 10-15 mg/kg IV every 8 hours 
to the initial empiric regimen51. 
Question 19: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Cytomegalovirus?
We suggest that empiric therapy be extended to cover the possibility of CAP due to 
Cytomegalovirus in patients with bilateral interstitial pneumonia after a recent lung transplant or 
hematopoietic stem cell transplant.
In these patients we suggest the addition of ganciclovir to the initial regimen at a dose of 5 
mg/kg IV every 12 hours, with dose adjustment for renal dysfunction52. Elevated plasma CMV 
viral loads are frequent in patients with CMV pneumonitis, but this finding alone is not sufficient 
for diagnosis53. In lung transplant recipients, CMV PCR viral load in BAL is a superior diagnostic 
tool than plasma CMV viral load54.
Question 20: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mycobacterium tuberculosis?
We suggest not to start empiric therapy to cover the possibility of CAP due to Mycobacterium 
tuberculosis.
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Pulmonary infections due to mycobacteria such as tuberculosis, are common in patients treated 
with TNF inhibitors and patients with long term high-dose steroids11. But in the case of 
suspected mycobacterial pneumonia we do not suggest treating the patient with empiric 
therapy. We suggest carrying out the indicated microbiological studies and begining treatment 
once the pathogen has been identified. We think that in these patients the risk-benefit of 
expanding empiric therapy with multiple mycobacterial drugs versus waiting to define which 
patients have a mycobacterial infection, is in favor of waiting for microbiological results and 
treating them specifically. 
An exception to this approach would be in patients with HIV infection with a history of 
recent exposure who have other clinical findings and radiographic features compatible with 
tuberculosis infection, and present with severe CAP. In this patients we will start empiric therapy 
for tuberculosis pending microbiologic work-up44. 
Question 21: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to parasites?
We suggest not to start empiric therapy to cover CAP due to parasites.
Parasites that can produce CAP in the immunocompromised host include Strongyloides 
stercoralis and Toxoplasma gondii55,56. 
Pneumonia in patients with Strongyloides hyperinfection syndrome may be due to 
invasion of lung tissue by the filariform larvae or with Gram-negative bacteremia secondary to 
seeding of the blood from the gastrointestinal tract. Patients at risk of Strongyloides 
hyperinfection syndrome include those with solid organ transplantation, hematopoietic stem cell 
transplantation, or patients with high and prolonged doses of corticosteroids (e.g. prednisone 
>20 mg per day, or its equivalent, for longer than 1 month) in combination with cytotoxic agents. 
Patients on this type of immune suppressing therapy, and also those with secondary 
bacteremias, may not have an elevated eosinophil count to raise suspicion of a parasitic 
infection. Therapy with ivermectin is recommended for patients with hyperinfection syndrome55. 
Toxoplasma pneumonia occurs due to reactivation of latent infection in (1) patients 
with HIV infection that is newly diagnosed, and not on antiretroviral therapy or with CD4 counts 
less than 100 cells/µl; or (2) patients with defects in cell-mediated immunity due to high and 
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prolonged doses of corticosteroids in combination with cytotoxic agents. Therapy with 
pyrimethamine and sulfadiazine is recommended for patients with Toxoplasma pneumonia44. 
We think that in these patients the risk benefit of expanding empiric therapy for 
parasitic infections or waiting to define which patients have a parasitic infection favors waiting 
for microbiological results and treat only the patients with a proven parasitic infection. 
DISCUSSION
In this document we have developed general suggestions for the initial management of the 
immunocompromised patient who arrives at the hospital with pneumonia. Despite our 
suggestions of empirical therapy for specific pathogens in specific situations, we stress the 
importance of making a concerted effort to establish a rapid and accurate etiologic diagnosis 
and to de-escalate complex therapies once a presumptive pathogen is properly ruled out. It is 
also important to consider local susceptibility patterns when selecting empiric therapy. The 
participants do suggest that, if evidence supports the presence of infections that require highly 
specialized management (e.g. cytomegalovirus or Mucorales), after initial therapy is begun, 
prompt transfer to a tertiary care facility should be strongly considered. Transfer to a specialized 
center may not be necessary if experienced pulmonary and infectious disease specialists are 
available to participate in management.
 
An important weakness of this document is the simplification of heterogenous 
conditions that affect different arms of the immune system into a single group of 
immunocompromised patients with CAP. Another limitation is that we were not able to provide 
references that appropriately support several of our suggestions, hence we need to emphasize 
the suggestions offered in this consensus are based primarily on expert opinion.
In conclusion, we have developed general suggestions for the initial management of 
immunocompromised patients hospitalized with pneumonia. When possible, the care of these 
patients should be carried out by a multidisciplinary group of specialists. Because 
immunocompromised patients have been excluded from prospective randomized studies of 
CAP treatment, there is an urgent need to generate scientific evidence in this field.
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Table 1. Questions addressing initial management strategies for community-acquired 
pneumonia (CAP) in immunocompromised adults.
A. Definition of Population
Question 1: Which patients with CAP should be considered immunocompromised?
B. Site of Care
Question 2: Which immunocompromised patients with CAP should be admitted to the hospital?
C. Likely Pathogens 
Question 3: What pathogens should be considered “core respiratory pathogens” in patients 
with CAP who are immunocompromised?
Question 4: What pathogens should be considered beyond the “core respiratory pathogens” in 
patients with CAP who are immunocompromised?
D. Microbiological Work-up
Question 5: What microbiological studies should be done in hospitalized patients with CAP 
who are immunocompromised?
Question 6: When should a bronchoscopy with bronchoalveolar lavage be performed in 
patients with CAP who are immunocompromised?
Question 7: What microbiological studies can be obtained in bronchoalveolar lavage in patients 
with CAP who are immunocompromised?
E. Empiric Therapy: General Principles
Question 8: What empiric therapy should be started in hospitalized patients with CAP who are 
immunocompromised?
Question 9: In which patients with CAP who are immunocompromised should empiric therapy 
be extended beyond the core respiratory pathogens?
Question 10: What role does the severity of pneumonia play in the selection of initial empiric 
therapy?
F. Empiric Therapy: Specific Pathogens
Question 11: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to MRSA?
Question 12: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of drug-resistant Gram-negative bacilli, including 
Pseudomonas aeruginosa?
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Question 13: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to multi-drug resistant (MDR) Gram-negative 
bacilli?
Question 14: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Pneumocystis jirovecii pneumonia (PCP)?
Question 15: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Aspergillus?
Question 16: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mucorales?
Question 17: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Nocardia?
Question 18: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Varicella-zoster virus?
Question 19: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Cytomegalovirus?
Question 20: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to Mycobacterium tuberculosis?
Question 21: In which immunocompromised patients should the initial empiric therapy be 
extended to cover the possibility of CAP due to parasites?
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Table 2. Patients with the following conditions should be considered immunocompromised
Primary immune deficiency diseases
Active malignancy or malignancy within one year prior to CAP, excluding patients with 
localized skin cancers or early stage cancers (e.g. stage 1 lung cancer)
Receiving cancer chemotherapy 
HIV infection with a CD4 T-lymphocyte count <200 cells/µl or percentage <14%*8
Solid organ transplantation 
Hematopoietic stem cell transplantation
Receiving corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent daily for ≥14 
days or a cumulative dose > 700 mg of prednisone**9,10
Receiving biologic immune modulators***11,12
Receiving disease-modifying anti-rheumatic drugs13 or other immunosuppressive drugs (e.g. 
cyclosporin, cyclophosphamide, hydroxychloroquine, methotrexate)
*The association of HIV disease and CAP can be categorized in 3 levels. 
Level 1: Patients with a CD4 T-lymphocyte count >500 cells/µl. These patients are not at 
increased risk of CAP. 
Level 2: Patients with a CD4 T-lymphocyte count between 500 to 200 cells/µl. These 
patients are at increased risk of CAP, but are not considered immunocompromised 
because the etiologic agents are the core CAP pathogens such as Streptococcus 
pneumoniae.  
Level 3: Patients with a CD4 T-lymphocyte count <200 cells/µl. These patients are at risk 
for CAP due to opportunistic pathogens such as PCP. They are considered 
immunocompromised patients with CAP. 
**In the case of patients taking steroid and CAP, both the daily dose and the cumulative dose of 
steroids should be considered. The association with CAP can be define in 3 levels.
Level 1: Doses ≤10 mg of prednisone a day and a cumulative dose of less than 600 mg 
of prednisone or equivalent. These patients are not at increased risk of CAP.
Level 2: Doses 10 mg to ≤ 20 mg of prednisone a day with a cumulative dose greater 
than 600 mg of prednisone or equivalent at the time of the CAP episode. These patients 
are at increased risk of CAP, but are not considered immunocompromised because the 
etiologic agents are the core CAP pathogens such as Streptococcus pneumoniae.  
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Level 3: Doses ≥20 mg or more of prednisone a day with a cumulative dose greater than 
600 mg of prednisone or equivalent at the time of the CAP episode. These patients are 
at risk for CAP due to opportunistic pathogens such as PCP. They are considered 
immunocompromised patients with CAP. Due to the cumulative dose of at least 600 mg, 
this patients need to be on steroid therapy for at least 3 to 4 weeks to be consider 
fulfilling this condition.
***These drugs are used to treat a wide array of inflammatory conditions and have multiple 
immunological targets. The diverse effects of these drugs include interfering with cell signaling, 
inhibiting cytokine function, interrupting innate immunity, depleting B cells, or inhibiting T-cell 
activation. Specific discussion of these drugs in detail is beyond the scope of this paper. 
However, nearly all immunomodulators carry some risk of infection. Because these 
immunomodulating agents affect different components of the immune system, the risk for 
specific infections varies with the target of the immunomodulator.
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Table 4: List of common respiratory pathogens in addition to core respiratory pathogens (as 
described in Table 3) that can cause CAP in the immunocompromised patient and for which 
antimicrobial therapy is available.
Bacteria Mycobacteria Viruses Fungi Parasites
Enterobacteriaceae
(Including those 


























Nocardia spp. Histoplasma spp.
Rhodococcus equi Cryptococcus spp.
Blastomyces spp.
Coccidioides spp.
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Table 5. Specific immune deficiencies and associated respiratory pathogens
Specific Immune Deficiency Unique Respiratory Pathogen Associations
Neutropenia Pseudomonas aeruginosa, Stenotrophomonas maltophilia, other 
Enterobacteriaceae, Streptococcus mitis, Staphylococcus aureus, 
Nocardia spp, Aspergillus and other hyaline molds (Scedosporium, 
Fusarium), yeast-like fungi (Trichosporon), Mucorales, dimorphic 
fungi
AIDS Pneumocystis jiroveci, Streptococcus pneumoniae, Mycobacterium 
tuberculosis, M. avium-intracellulare complex and other non-
tuberculous mycobacteria, Histoplasma capsulatum, Coccidioides, 
Bartonella, Rhodococcus, Toxoplasma gondii, Cryptococcus 
neoformans, Cryptosporidium, Nocardia, Talaromycosis marneffei, 
Paracoccidioides, Burkholderia, Cytomegalovirus,  Strongyloides
T-cell depletion (Antithymocyte 
globulin, Alemtuzumab)
Pneumocystis jiroveci, Streptococcus pneumoniae, Mycobacterium 
tuberculosis, M. avium-intracellulare complex and other non-
tuberculous mycobacteria, Aspergillus and other hyaline molds, 
Mucorales spp, Varicella, Herpes simplex, Cytomegalovirus, 
Histoplasma capsulatum, Coccidioides, Bartonella spp., Toxoplasma 





Myeloma, Therapies that target 
CD19/20, e.g. rituximab)
Respiratory viruses (Influenza, RSV, HMPV, Parainfluenza, 
Adenovirus, Enterovirus), Encapsulated bacteria (S. pneumoniae, 
Moraxella catarrhalis, Haemophilus influenzae, S. aureus, 




Legionella, Nocardia, Aspergillus and other hyaline mold, Mucorales 
spp, Cytomegalovirus, endemic fungi
Antimetabolites (mycophenolate 
mofetil, azathioprine, 6-MP, 
fludarabine)
Cytomegalovirus, Varicella, Respiratory viruses (if B-cell 
impairment), Legionella, Nocardia, Aspergillus and other hyaline 
mold, Mucorales spp, endemic fungi, (Pneumocystis– fludarabine)
Mammalian target of rapamycin 
(mTOR) inhibitors (sirolimus, 
evirolimus)
Cryptococcus, Pneumocystis
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Tumor Necrosis Factor (TNF) 
Inhibitors
Endemic fungi, Aspergillus, Mycobacteria (tuberculous and non-
tuberculous), Varicella, Nocardia, Pneumocystis
Janus kinase (JAK) Signaling 
Inhibitors (e.g. Ibrutinib, Dasatinib)
Pneumocystis, mold, Cytomegalovirus
Corticosteroids Bacteria, esp. Pseudomonas aeruginosa, Pneumocystis jiroveci, 
Staphylococcus aureus, Mycobacteria, Aspergillus and other hyaline 
molds, Mucorales spp, Cytomegalovirus , Varicella, Herpes simplex, 
Cytomegalovirus, Histoplasma capsulatum, Coccidioides, 
Cryptococcus neoformans, Nocardia, Legionella, Strongyloides
Other Natalizumab (Cryptococcus), vedolizumab (M. tuberculosis), 
Tocilizumab (unknown), Ustekinumab (theoretical CMV), 
Secukinumab (theoretical mold), eculizumab (Pseudomonas, mold), 
bortezemib (Varicella zoster)
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Table 6. Microbiological studies that can be obtained in immunocompromised patients 
hospitalized with CAP
Sputum samples for bacterial, mycobacterial, and fungal stains and cultures
Comments: Sputum can be induced using inhaled isotonic or preferably hypertonic saline for 
certain pathogens (e.g., MTB, PCP) in order to avoid invasive procedures. Sputum samples 
can be tested using PCR for detection of MTB or PCP20,21. 
Nasopharyngeal swab with PCR multiplex for respiratory viruses
Comments: A negative nasopharyngeal PCR does not rule out viral pneumonia.  If the 
suspicion is high, perform the PCR on bronchoscopic samples22,23. The finding of a virus by 
PCR does not rule out bacterial infection.
Nasopharyngeal swab with PCR multiplex for atypical bacteria
Comments: Atypical pathogens such as Legionella, Chlamydophila, or Mycoplasma, can also 
be identified in oropharyngeal samples.
Nasal PCR for MRSA
Comments: Use in conjunction with a respiratory sample. A negative MRSA nasal PCR, the 
absence of Gram-positive cocci in clusters on Gram's stain, and a negative MRSA respiratory 
culture make MRSA pneumonia extremely unlikely.
Blood cultures times two (at least) 30 minutes apart 
Comments: If there is a PORT or central line or PICC line, to define the presence of line 
infection, perform blood cultures from a peripheral vein and from the catheter lumens at the 
same time to calculate “time to positivity"24. The separation of samples over time improve 
bacterial detection in case of intermittent bacteremia25.
Urinary antigen for Streptococcus pneumoniae
Comments: The recent administration of pneumococcal vaccine (within days) will produce a 
positive urinary antigen for Streptococcus pneumoniae. 
Urinary antigen for Legionella
Comments: Detects only Legionella pneumophila serotype 1. Other Gram-negative bacteria 
may generate a false positive test26. Obtain respiratory samples for culture and PCR to detect 
other species of Legionella or serotypes if clinically indicated. 
Urinary antigen for Histoplasma capsulatum 
Comments: Very useful for disseminated disease. Cross reaction with blastomycosis.
Serum antigen for Cryptococcus neoformans
Comments: A serum cryptococcal antigen test may be negative in a patient with documented 
cryptococcal pneumonia. 
Serum galactomannan antigen
Comments: Aspergillus cell wall contains the polysaccharide galactomannan.  Also elevated 
in Fusarium, Penicillium, blastomycosis, and histoplasmosis. False positives may occur with 
IVIG, transfusions and some beta-lactam antibiotics27.
Serum 1,3-Beta-D-glucan 
Comments: Beta-D-glucan is a cell component of several fungi. It screens for Aspergillus 
spp., Candida spp., PCP, and other fungi. It does not detect mucormycosis. False positives 
may occur with IVIG, hemodialysis with cellulose, albumin, infections by Pseudomonas, and 
some beta-lactam antibiotics27.
Swabs of vesicular or ulcerated skin lesions for viral PCR and cultures
Comments: A positive PCR for HSV or VZV from skin lesions is highly correlated with herpes 
or varicella pneumonia.
Biopsy of skin lesion for microbiology & pathology
Comments: Sample must be sent to microbiology and pathology for stains and cultures for 
viruses, bacteria, mycobacteria, fungi and parasites.
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Viral load for CMV (PCR)
Comments: Obtain only if clinical suspicion is high. CMV reactivation is common in acute 
illness and the presence of copies of CMV in plasma does not necessarily indicate invasive 
disease. On the other hand, the absence of viremia makes CMV pneumonitis less likely28.
Viral load for Adenovirus
Comments: Obtain only if clinical suspicion is high29.
Serology for Histoplasmosis, Coccidioidomycosis and Blastomycosis
Comments: Fungal serology is not generally recommended in immunosuppressed patients 
since they fail to generate an adequate antibody response to infection27. 
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Table 7. Microbiological studies in BAL fluid or tranbronchial lung biopsy
Bacteria Gram’s stain and culture   
Comments: A negative stain and culture of MDR pathogens (e.g. MRSA) can be used for de-
escalation of therapy unless antibiotics have been given for >48 hours.
MRSA PCR
Comments: A negative PCR for MRSA can be used for de-escalation of anti-MRSA therapy 
unless antibiotics have been given for >48 hours31.
AFB stains and culture for tuberculous and non-tuberculous mycobacteria
Comments: If positive AFB stain, nucleic acid amplification (NAA) tests allows for rapid 
diagnosis. NAA test can be performed if the AFB stain is negative and the suspicion of 
disease is high20.
Nocardia stains and culture
Comments: AFB stain may be weakly positive.
Fungal stains and culture
Comments: Since Aspergillus can colonize the airways, positive stains or culture of 
Aspergillus species from respiratory samples do not necessarily indicate disease27.
PCP stains and PCR
Comments: In patients with PCP, the sensitivity of staining is higher in HIV-infected patients 
when compared to HIV-uninfected patients. A positive PCR may occur in patients colonized 
with PCP. In non-HIV patients, a negative PCR can be use to discontinue anti-PCP therapy32.
Respiratory Viral Panel with multiplex PCR 
Comments: Viruses can be detected in BAL by PCR in a patient with a negative 
nasopharyngeal swab PCR for the same virus22,23.
Atypical pathogens panel with multiplex PCR 
Comments: A positive PCR is considered diagnostic for atypical pneumonia since pathogens 
such as Legionella, Chlamydophila, or Mycoplasma rarely colonize the airway. 
Galactomannan Antigen
Comments: The cell wall of Aspergillus contain the polysaccharide galactomannan. Other 
fungi that contain galactomannan include Histoplasma capsulatum, Penicillium species and 
Fusarium species. False positive levels may occur in BAL samples with some beta-lactam 
antibiotics27. 
Aspergillus PCR 
Comments: The high sensitivity of PCR produce a high negative predictive value, making the 
diagnosis unlikely with a negative test27. 
(1,3)-Beta-D-glucan
Comments: It is considered a poor screening tool for the diagnosis of invasive fungal 
infections due to its low positive predictive value27.
CMV PCR
Comments: Quantitative PCR analysis in BAL fluid may help to differentiate between CMV 
pneumonia (high viral load) versus CMV pulmonary shedding without pneumonia (low viral 
load) but cut-off levels are not defined33.
Cellular analysis
Comments: A predominantly inflammatory cellular pattern in the BAL with neutrophil 
pleocytosis can be used as a predictor of bacterial etiology34,35.
Histopathology
Comments: Routine hematoxylin and eosin (H&E) staining, special stains, and culture for 
viruses, bacteria, mycobacteria, fungi and parasites.
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The goal of this project was to generate a consensus document on the initial management of community-
acquired pneumonia (CAP) in the immunocompromised patient (ICP). Consensus was reached by using 
the Delphi survey method. In this supplemental material, we will describe: 1) the methodology used for 
the Delphi survey, and 2) the level of agreement for each of the recommendations. 
 
1. Delphi survey methodology 
We started this process with a core group of two infectious diseases physicians and four pulmonary 
physicians. After a full review of the English literature in the topic of management of CAP in the ICP, the 
initial Delphi questions used in the survey were developed. The core group performed several initial 
versions of the manuscript to reach a basic level of agreement regarding the answers for each of the 
Delphi survey questions. The following 5-point Likert scale was used to evaluate agreement or 
disagreement with each proposed answer: Strongly Disagree (1), Disagree (2), Neutral (3), Agree (4), 
Strongly Agree (5). It was considered that a consensus was reached once more than 75% of participants 
agreed or strongly agreed with a particular recommendation.  
 
Once the basic document was developed, the first round of the Delphi questions regarding the 
management of CAP in the ICP were submitted to all 45 participants of the consensus. To anonymously 
record participant responses and comments, a survey was developed using Research Electronic Data 
Capture (REDCap) that allowed participants to answer with their level of agreement with the suggested 
recommendations and to write specific comments regarding the management suggested by the group. 
 
After the first round of the survey was completed, all responses were summarized and plot using a 
bar chart to identify patterns and to indicate the level of agreement for each section of the manuscript. An 
anonymized summary of all the comments was produced. Each participant received the bar chart results 
and a summary of the comments and suggestions. Participants have the opportunity to revise the earlier 
answers considering the anonymized replies of other members of the panel. Additionally, we identified two 
areas with a significant level of disagreement. 
 
For the second round of the survey, we focused only in these two areas of disagreement, which 
allowed the group to concentrate the discussion on the two questions with the highest level of 
disagreement. To reach agreement, some of the original questions were divided into new, more specific 
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questions. After a better level of agreement was achieved for these questions, a third round of all 
questions were circulated among the group. 
 
After the participants answered the third round of all questions, the range of the answers 
decreased significantly and it was considered that group had reached consensus. At that point, a pre-final 
manuscript was created and submitted to all participants for final comments and agreement ratings. After 
the final comments were incorporated, the manuscript was produced.  
 
Statistical analysis 
At each round of the survey, we calculated the mean and standard deviation of agreement based on the 
Likert scale for each question. To evaluate the level of agreement/disagreement for each question in a 
manner that incorporated both mean and standard deviation, we calculated a t-statistic for each question. 
This way, we could identify the questions, which had the least agreement or most controversy. Agreement 
was visualized by bar charts, and final agreement was reported as percentage of participants who 
responded as Agree or Strongly Agree. 
 
2. Level of agreement for each section of the manuscript 
 
Level of agreement with the Introduction  
 
Agreement with the statements mentioned in the introduction of the manuscript was achieved in 44 of the 
45 participants (98%). Initial agreement was also 98%. Results of the Likert scale for the introduction of 
the manuscript are depicted in the bar chart below.  
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Level of agreement with Question 1: Which patients with CAP should be considered immunocompromised? 
 
Agreement with the answer to question 1 was achieved in 45 of the 45 participants (100%). Initial 
agreement for the original, proposed answer to question 1 was 93%. Results of the Likert scale for 
question 1 are depicted in the bar chart below.  
 
 
Additional comments for Question 1:  
In patients without spleen, even though they are at increased risk for pneumonia, the organisms causing 
pneumonia are still the common organisms that cause CAP. Since patients without spleen are not at risk 
for opportunistic pathogens, they were not considered in this definition of immunocompromised. The same 
concept applies to patients on inhaled corticosteroids. 
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Level of agreement with Question 2: Which immunocompromised patients with CAP should be admitted to 
the hospital? 
 
Agreement with the answer to question 2 was achieved in 44 of the 45 participants (98%). Initial 
agreement for the original, proposed answer to question 2 was 86%. Results of the Likert scale for 
question 2 are depicted in the bar chart below.  
 
 
Additional comments for Question 2:  
Immunosuppressive drugs are known to modulate the inflammatory response, thus the typical signs and 
symptoms of CAP may be attenuated in these patients. This blunted inflammatory response may also 
produce low levels of inflammatory markers. Because of this, it was considered not to use inflammatory 
biomarkers when determining the need for hospitalization. 
 
Additionally, some experts considered that all immunocompromised patients with CAP should be admitted 
to the hospital. Few would manage some of these patients in the outpatient setting, as long as patients 
can have a close follow-up and rapid mechanism to be seen if clinical deterioration occurs. This clinical 
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Level of agreement with Question 3: What pathogens should be considered “core respiratory pathogens” 
in patients with CAP who are immunocompromised? 
 
Agreement with the answer to question 3 was achieved in 44 of the 45 participants (98%). Initial 
agreement for the original, proposed answer to question 3 was 77%. Results of the Likert scale for 




Page 50 of 68
































































Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 4: What pathogens should be considered beyond the “core respiratory 
pathogens” in patients with CAP who are immunocompromised? 
 
Agreement with the answer to question 4 was achieved in 41 of the 45 participants (91%). Initial 
agreement for the original, proposed answer to question 4 was 84%. Results of the Likert scale for 
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Level of agreement with Question 5: What microbiological studies should be done in hospitalized patients 
with CAP who are immunocompromised? 
 
Agreement with the answer to question 5 was achieved in 41 of the 45 participants (91%). Initial 
agreement for the original, proposed answer to question 5 was 66%. Results of the Likert scale for 
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Level of agreement with Question 6: When should a bronchoscopy with bronchoalveolar lavage be 
performed in patients with CAP who are immunocompromised? 
 
Agreement with the answer to question 6 was achieved in 41 of the 45 participants (91%). Initial 
agreement for the original, proposed answer to question 6 was 66%. Results of the Likert scale for 
question 6 are depicted in the bar chart below. 
 
 
Additional comments for question 6: 
Some experts wanted to emphasize the need for bronchoscopy in the immunocompromised population. In 
these patients more than one causative agent may play a role as a cause of pneumonia and there is 
additional value of bronchoscopy in defining non-infectious etiologies of pulmonary infiltrates. On the other 
hand, some experts considered that bronchoscopy was associated with significant side effects. 
 
The use of next generation sequencing (NGS) in the field of pneumonia diagnosis using BAL fluid is rapidly 
evolving. Real-time metagenomics can be used to identify respiratory pathogens from BAL fluid in 
immunocompromised patients with pneumonia. This culture-independent technique for pathogen 
identification can generate results faster than the traditional culture techniques. Current challenges for 
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widespread application of NGS include the cost and the fact that the analysis requires substantial 
computational skills and resources. 
 
BAL fluid is typically obtained after the introduction of the bronchoscope into the tracheobronchial tree and 
the inspection of the airway. Mini-BAL is a blind non-bronchoscopic procedure to obtain samples in 
patients on mechanical ventilation. Mini-BAL sampling can be obtained using telescoping catheters. These 
techniques have been primarily studied in patients with VAP, but may be considered in 




Level of agreement with Question 7: What microbiological studies can be obtained in bronchoalveolar 
lavage in patients with CAP who are immunocompromised? 
 
Agreement with the answer to question 7 was achieved in 43 of the 45 participants (96%). Initial 
agreement for the original, proposed answer to question 7 was 66%. Results of the Likert scale for 
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Level of agreement with Question 8: What empiric therapy should be started in hospitalized patients with 
CAP who are immunocompromised? 
 
Agreement with the answer to question 8 was achieved in 42 of the 45 participants (93%). Initial 
agreement for the original, proposed answer to question 8 was 60%. Results of the Likert scale for 
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Level of agreement with Question 9: In which patients with CAP who are immunocompromised should 
empiric therapy be extended beyond the core respiratory pathogens? 
 
Agreement with the answer to question 9 was achieved in 42 of the 45 participants (93%). Initial 
agreement for the original, proposed answer to question 9 was 86%. Results of the Likert scale for 
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Level of agreement with Question 10: What role does the severity of pneumonia play in the selection of 
initial empiric therapy? 
 
Agreement with the answer to question 10 was achieved in 39 of the 45 participants (87%). Initial 
agreement for the original, proposed answer to question 10 was 83%. Results of the Likert scale for 
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Level of agreement with Question 11: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to MRSA? 
 
Agreement with the answer to question 11 was achieved in 42 of the 45 participants (93%). Initial 
agreement for the original, proposed answer to question 11 was 60%. Results of the Likert scale for 
question 11 are depicted in the bar chart below. 
 
Additional 
comments for Question 11: 
There was some debate over what would be considered a “low” MRSA prevalence. The recently published 
HAP and VAP guidelines from the ATS/IDSA suggest that an MRSA prevalence of 25% or above should 
trigger the use of anti-MRSA therapy, but the authors recognize that there is no solid epidemiological data 
to support this recommendation. In the guidelines document, the authors express the following: “We 
acknowledge that, given the lack of data to inform optimal thresholds for broadening coverage, individual 
units can adjust these thresholds in accordance with local values and preferences.” We face a similar 
problem with the lack of data to inform an optimal epidemiologic threshold in patients with CAP. 
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Level of agreement with Question 12: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of drug-resistant Gram-negative bacilli, including 
Pseudomonas aeruginosa? 
 
Agreement with the answer to question 12 was achieved in 42 of the 45 participants (93%). Initial 
agreement for the original, proposed answer to question 12 was 60%. Results of the Likert scale for 
question 12 are depicted in the bar chart below. 
 
 
Additional comments for question 12: 
The consensus from the Delphi survey concluded that in the context of CAP treatment, drug resistant 
gram-negative bacilli refers to organisms that are resistant to the standard beta-lactam antibiotics used 
for the treatment of CAP. Using the traditional approach of empiric therapy of ceftriaxone plus 
azithromycin any Pseudomonas aeruginosa will be a drug resistant pathogen as they are routinely 
resistant to ceftriaxone. The implication of a drug-resistant gram negative bacilli is the need to extend the 
coverage of the beta-lactam antibiotic to cover Pseudomonas aeruginosa. Appropriate beta-lactam 
antibiotics in this situation may be piperacillin-tazobactam or ceftazidime. 
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Level of agreement with Question 13: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to multi-drug resistant (MDR) Gram-negative 
bacilli? 
 
Agreement with the answer to question 13 was achieved in 43 of the 45 participants (96%). Initial 
agreement for the original, proposed answer to question 13 was 91%. Results of the Likert scale for 
question 13 are depicted in the bar chart below. 
 
 
Additional comments for question 13: 
The consensus from the Delphi survey concluded that MDR gram-negative rods are considered organisms 
that would be resistant to the first line of beta-lactam antibiotics used for the treatment of Pseudomonas 
aeruginosa or other gram-negative rods. These would be gram negative rods resistant to piperacillin-
tazobactam or ceftazidime or even carbapenems. In this clinical scenario, the empiric therapy would need 
to escalate to new beta-lactam antibiotics or new beta-lactamase inhibitors. 
 
  
Page 60 of 68
































































Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 14: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Pneumocystis jirovecii pneumonia (PCP)? 
 
Agreement with the answer to question 14 was achieved in 43 of the 45 participants (96%). Initial 
agreement for the original, proposed answer to question 14 was 90%. Results of the Likert scale for 
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Level of agreement with Question 15: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Aspergillus? 
 
Agreement with the answer to question 15 was achieved in 43 of the 45 participants (96%). Initial 
agreement for the original, proposed answer to question 15 was 69%. Results of the Likert scale for 
question 15 are depicted in the bar chart below. 
 
 
Additional comments for question 15: 
Due to the superposition of risk factors (e.g. cancer and chemotherapy, severe and prolonged 
neutropenia, and radiographic nodular pattern), the initial empiric therapy should be performed with an 
anti-fungal that covers the possibility of both Aspergillus and Mucorales. We also strongly suggest 
extensive microbiological workup to allow for de-escalation of therapy and continuation of treatment of 
Aspergillus with a narrow spectrum antifungal. 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 16: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Mucorales? 
 
Agreement with the answer to question 16 was achieved in 41 of the 45 participants (91%). Initial 
agreement for the original, proposed answer to question 16 was 70%. Results of the Likert scale for 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 17: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Nocardia? 
 
Agreement with the answer to question 17 was achieved in 42 of the 45 participants (93%). Initial 
agreement for the original, proposed answer to question 17 was 71%. Results of the Likert scale for 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 18: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Varicella-zoster virus? 
 
Agreement with the answer to question 18 was achieved in 44 of the 45 participants (98%). Initial 
agreement for the original, proposed answer to question 18 was 95%. Results of the Likert scale for 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 19: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Cytomegalovirus? 
 
Agreement with the answer to question 19 was achieved in 44 of the 45 participants (98%). Initial 
agreement for the original, proposed answer to question 19 was 85%. Results of the Likert scale for 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 20: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to Mycobacterium tuberculosis? 
 
Agreement with the answer to question 20 was achieved in 45 of the 45 participants (100%). Initial 
agreement for the original, proposed answer to question 20 was 68%. Results of the Likert scale for 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with Question 21: In which immunocompromised patients should the initial empiric 
therapy be extended to cover the possibility of CAP due to parasites? 
 
Agreement with the answer to question 21 was achieved in 45 of the 45 participants (100%). Initial 
agreement for the original, proposed answer to question 21 was 82%. Results of the Likert scale for 
question 21 are depicted in the bar chart below. 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Level of agreement with the Conclusion 
 
Agreement with the statements mentioned in the conclusion of the manuscript was achieved in 43 of the 
45 participants (96%). Initial agreement with the concluding statements was 87%. Results of the Likert 
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BAL:  bronchoalveolar lavage  
CAP:  community-acquired pneumonia  
CMV:  Cytomegalovirus 
CRE:   carbapenemase-producing Enterobacteriaceae  
DMARDs: disease-modifying anti-rheumatic drugs 
ESBL:   extended spectrum beta-lactamase  
HIV:  human immunodeficiency virus 
MDR:   multiple drug resistant 
NTM:  non-tuberculous Mycobacteria  
PCP:  Pneumocystis jirovecii  
PCR:   polymerase chain reaction 
PSI:  Pneumonia Severity Index  
TMP-SMX:  trimethoprim-sulfamethoxazole 
TNF:   tumor necrosis factor  
 
